,DTH/Антиген,DTH/Качественное значение,DTH/Количественное значение до иммунизации,DTH/Количественное значение после иммунизации,ELISPOT/Антиген,ELISPOT/Качественное значение,ELISPOT/Количественное значение до иммунизации,ELISPOT/Количественное значение после иммунизации,Адъювант в составе вакцины/Значение,Антиген-специфические лимфоциты in vitro/Антиген,Антиген-специфические лимфоциты in vitro/Качественное значение,Вакцинация/ГРУППА: наибольшее значение кол-ва введенных клеток,Вакцинация/ГРУППА: наименьшее значение кол-ва введенных клеток,Вакцинация/Кол-во клеток введенных за одну вакцинацию,Вакцинация/Количество вакцинаций,Вакцинация/Общее количество введенных клеток,Возраст/ГРУППА: наибольшее значение,Возраст/ГРУППА: наименьшее значение,Возраст/Точное значение или медиана (для группы),Выживаемость/Единицы измерения,Выживаемость/Результат,Выживаемость/Срок дожития/наблюдения,Гаплотип/Значение,Диагноз/Значение,Иммунный статус до иммунизации/Значение,Индекс ECOG/ГРУППА: наибольшее значение,Индекс ECOG/ГРУППА: наименьшее значение,Индекс ECOG/Точное значение или медиана (для группы),Индекс Карновского/ГРУППА: наибольшее значение,Индекс Карновского/ГРУППА: наименьшее значение,Индекс Карновского/Точное значение или медиана (для группы),Индукторы созревания ДК/Значение,Источник дендритных клеток/Значение,Лечение до иммунизации/Значение,Объективный клинический ответ/Значение,Опухолевые маркеры/Качественное значение,Опухолевые маркеры/Количественное значение до вакцинации,Опухолевые маркеры/Количественное значение после вакцинации,Опухолевые маркеры/Тип маркера,Побочные эффекты/Значение,Пол/Значение,Раса/Значение,Сопутствующая терапия/Значение,Способ введения вакцины/Значение,Стадия заболевания/Значение,Тип вакцины/Значение
0,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,,,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
3,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Chemotherapy,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
4,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Surgery,,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
5,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Radiotherapy,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
6,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,,Stable Desease,Decrease,,,PSA,Not significant,Male,,Immunotherapy,Intravenously,,Protein
7,,,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,,Stable Desease,Decrease,,,PSA,Not significant,Male,,Immunotherapy,Intravenously,,Protein
8,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Surgery,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
9,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Surgery,,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
10,,,,,,,,,KLH,Control antigen,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
11,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Radiotherapy,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
12,,,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,,,Decrease,,,PSA,Not significant,Male,,Immunotherapy,Intravenously,,Protein
13,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,,Stable Desease,Decrease,,,PSA,Not significant,Male,,Immunotherapy,Intravenously,,Protein
14,,,,,,,,,KLH,Control antigen,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
15,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
16,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Chemotherapy,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
17,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Radiotherapy,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
19,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,,Stable Desease,Decrease,,,PSA,Not significant,Male,,Immunotherapy,Intravenously,,Protein
20,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
21,,,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Surgery,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
22,,,,,,,,,KLH,Control antigen,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
23,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Radiotherapy,,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
24,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Surgery,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
25,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Chemotherapy,,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
26,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Chemotherapy,Stable Desease,Decrease,,,PSA,Not significant,Male,,Immunotherapy,Intravenously,,Protein
28,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29,,,,,,,,,KLH,Control antigen,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
30,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Surgery,,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
31,,,,,,,,,,,,,,,8.0,10000000.0,,,,,,,HLA-A1,Melanoma,Normal,,,,,,100.0,TNF-α,HSC,Chemotherapy,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Peptide
32,,,,,,,,,,Tumor antigen,No,,,,12.0,10000000.0,,,,,,,HLA-A2,Melanoma,Normal,,,,,,100.0,TNF-α,HSC,Surgery,Not evaluable,,,,,Not significant,Male,,,Intravenously,,Peptide
33,Tumor antigen,Yes,,,Tumor antigen,No,,,,,,,,,4.0,5000000.0,,,,,,,HLA-A1,Melanoma,Normal,,,,,,90.0,TNF-α,HSC,Surgery,Progressive Disease,,,,,Not significant,,,,Intravenously,,Peptide
34,,,,,Tumor antigen,No,,,,Tumor antigen,No,,,,7.0,5000000.0,,,,,,,HLA-A2,Melanoma,Normal,,,,,,100.0,TNF-α,HSC,Chemotherapy,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Peptide
35,Tumor antigen,Yes,,,Tumor antigen,No,,,,,,,,,8.0,10000000.0,,,,,,,HLA-A2,Melanoma,Normal,,,,,,100.0,TNF-α,HSC,Chemotherapy,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Peptide
36,,,,,Tumor antigen,No,,,,,,,,,4.0,10000000.0,,,,,,,HLA-A1,Melanoma,Normal,,,,,,90.0,TNF-α,HSC,Surgery,Progressive Disease,,,,,Not significant,Female,,,Intravenously,,Peptide
37,,,,,,,,,,,,,,,4.0,10000000.0,,,,,,,HLA-A2,Melanoma,Normal,,,,,,90.0,TNF-α,HSC,Chemotherapy,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Peptide
38,,,,,Tumor antigen,No,,,,,,,,,8.0,10000000.0,,,,,,,HLA-A1,Melanoma,Normal,,,,,,,TNF-α,HSC,Surgery,Partial Response,,,,,Not significant,Male,,,Intravenously,,Peptide
39,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,4.0,10000000.0,,,,,,,HLA-A2,Melanoma,Normal,,,,,,100.0,TNF-α,HSC,Chemotherapy,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Peptide
40,Tumor antigen,Yes,,,Tumor antigen,No,,,,,,,,,8.0,10000000.0,,,,,,,HLA-A2,Melanoma,Normal,,,,,,100.0,TNF-α,HSC,Chemotherapy,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Peptide
41,,,,,,,,,,,,,,,4.0,10000000.0,,,,,,,HLA-A1,Melanoma,Normal,,,,,,80.0,TNF-α,HSC,Chemotherapy,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Peptide
42,,,,,Tumor antigen,No,,,,Tumor antigen,No,,,,4.0,50000000.0,,,,,,,HLA-A2,Melanoma,Normal,,,,,,80.0,TNF-α,HSC,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Peptide
43,,,,,,,,,,Tumor antigen,No,,,,4.0,50000000.0,,,,,,,HLA-A1,Melanoma,Normal,,,,,,,TNF-α,HSC,Surgery,Progressive Disease,,,,,Not significant,,,,Intravenously,,Peptide
44,,,,,,,,,,Tumor antigen,No,,,,4.0,50000000.0,,,,,,,HLA-A2,Melanoma,Normal,,,,,,,TNF-α,HSC,Chemotherapy,Stable Desease,,,,,Not significant,,,,Intravenously,,Peptide
45,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
46,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
47,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
48,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
49,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
50,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
51,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
52,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
53,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
54,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
55,,,,,,,,,,Tumor antigen,Yes,,,,2.0,3200000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Protein
56,,,,,,,,,,Tumor antigen,Yes,,,,2.0,6300000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Protein
57,,,,,,,,,,,,,,,2.0,14900000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Radiotherapy,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Protein
58,,,,,,,,,,Tumor antigen,Yes,,,,2.0,3400000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Protein
59,,,,,,,,,,,,,,,2.0,4800000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Radiotherapy,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Protein
60,,,,,,,,,,Tumor antigen,Yes,,,,2.0,17700000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Protein
61,,,,,,,,,,Tumor antigen,Yes,,,,2.0,7600000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Protein
62,,,,,,,,,,Tumor antigen,Yes,,,,2.0,14900000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Protein
63,,,,,,,,,,Tumor antigen,Yes,,,,2.0,18600000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Protein
64,,,,,,,,,,Tumor antigen,Yes,,,,2.0,24400000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,,Progressive Disease,,,,,Not significant,Male,,,Intradermal,,Protein
65,,,,,,,,,,,,,,,2.0,2300000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Radiotherapy,Stable Desease,,,,,Not significant,Male,,,Intradermal,,Protein
66,,,,,,,,,,Tumor antigen,Yes,,,,2.0,14600000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,,Progressive Disease,,,,,Not significant,Male,,,Intradermal,,Protein
67,,,,,,,,,,,,,,,2.0,10600000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Radiotherapy,Progressive Disease,,,,,Not significant,Male,,,Intradermal,,Protein
68,,,,,,,,,,Tumor antigen,Yes,,,,2.0,5100000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intradermal,,Protein
69,,,,,,,,,,Tumor antigen,Yes,,,,2.0,22700000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,,Stable Desease,,,,,Not significant,Male,,,Intradermal,,Protein
70,,,,,,,,,,,,,,,2.0,9500000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,,Progressive Disease,,,,,Not significant,Male,,,Intralymphatically,,Protein
71,,,,,,,,,,,,,,,2.0,14400000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Radiotherapy,Progressive Disease,,,,,Not significant,Male,,,Intralymphatically,,Protein
72,,,,,,,,,,,,,,,2.0,26900000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Radiotherapy,Progressive Disease,,,,,Not significant,Male,,,Intralymphatically,,Protein
73,,,,,,,,,,Tumor antigen,Yes,,,,2.0,2600000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,,Progressive Disease,,,,,Not significant,Male,,,Intralymphatically,,Protein
74,,,,,,,,,,,,,,,2.0,9700000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Radiotherapy,Stable Desease,,,,,Not significant,Male,,,Intralymphatically,,Protein
75,,,,,,,,,,Tumor antigen,Yes,,,,2.0,10300000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,,Stable Desease,,,,,Not significant,Male,,,Intralymphatically,,Protein
76,,,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,100000.0,,,55.0,,,,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,,
77,Tumor antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,100000.0,,,59.0,,,,,,,,,,,,,,,Surgery,Complete response,,,,,,Male,,,,,
78,Control antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,250000.0,,,43.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
79,Tumor antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,100000.0,,,42.0,,,,,,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,Female,,,,,
80,Control antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,250000.0,,,45.0,,,,,,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,Male,,,,,
81,Tumor antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,100000.0,,,36.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
82,Control antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,500000.0,,,61.0,,,,,,,,,,,,,,,Surgery,Partial Response,,,,,,Female,,,,,
83,Control antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,250000.0,,,44.0,,,,,,,,,,,,,,,Immunotherapy,Complete response,,,,,,Male,,,,,
84,Tumor antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,500000.0,,,50.0,,,,,,,,,,,,,,,Surgery,Complete response,,,,,,Male,,,,,
85,Tumor antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,1000000.0,,,56.0,,,,,,,,,,,,,,,Surgery,Partial Response,,,,,,Female,,,,,
86,,,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,,,,4.0,500000.0,,,50.0,,,,HLA-A201,Melanoma,Normal,,,,,80.0,,Flt3L,HSC,Surgery,Progressive Disease,,,,,None,Male,,,Subcutaneously,Metastatic,Peptide
87,Tumor antigen,Yes,,,Control antigen,Yes,,,,,,,,,,1000000.0,,,43.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
88,Control antigen,Yes,,,Control antigen,Yes,,,,,,,,,,250000.0,,,73.0,,,,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,,
89,Tumor antigen,Yes,,,,,,,,Tumor antigen,Yes,,,,,500000.0,,,57.0,,,,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
90,Tumor antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,1000000.0,,,70.0,,,,,,,,,,,,,,,Surgery,Partial Response,,,,,,Female,,,,,
91,Tumor antigen,Yes,,,Control antigen,Yes,,,,,,,,,,100000.0,,,66.0,,,,,,,,,,,,,,,Radiotherapy,Not evaluable,,,,,,Male,,,,,
92,Tumor antigen,Yes,,,Control antigen,Yes,,,,,,,,,,1000000.0,,,40.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
93,,,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,1000000.0,,,66.0,,,,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
94,Tumor antigen,Yes,,,,,,,KLH,,,,,,14.0,,,,53.0,,,,HLA-A1,Thyroid Cancer,,,,,,,,TNF-α,Monocytes,Surgery,Stable Desease,Decrease,,,PSA,None,Female,,,Intracutaneously,,Peptide
95,Control antigen,Yes,,,,,,,,,,,,,14.0,,,,62.0,,,,HLA-A1,,,,,,,,,,,Surgery,Stable Desease,Decrease,,,PSA,Not significant,Male,,,,,Co-culture
96,Control antigen,Yes,,,,,,,KLH,,,,,,12.0,,,,37.0,,,,HLA-A2,Thyroid Cancer,,,,,,,,TNF-α,Monocytes,Surgery,Partial Response,Decrease,,,PSA,None,Male,,,Intracutaneously,,Peptide
97,Control antigen,Yes,,,,,,,KLH,,,,,,10.0,,,,32.0,,,,HLA-A2,Thyroid Cancer,,,,,,,,TNF-α,Monocytes,Surgery,Stable Desease,Decrease,,,PSA,Not significant,Female,,,Intracutaneously,,Peptide
98,Control antigen,Yes,,,,,,,KLH,,,,,,11.0,,,,58.0,,,,HLA-A1,Thyroid Cancer,,,,,,,,TNF-α,Monocytes,Surgery,Stable Desease,Decrease,,,PSA,Not significant,Female,,,Intracutaneously,,Peptide
99,Control antigen,Yes,,,,,,,KLH,,,,,,11.0,,,,31.0,,,,HLA-A2,Thyroid Cancer,,,,,,,,TNF-α,Monocytes,Surgery,Stable Desease,Decrease,,,PSA,Not significant,Male,,,Intracutaneously,,Peptide
100,Control antigen,Yes,,,,,,,KLH,,,,,,7.0,,,,38.0,,,,HLA-A2,Thyroid Cancer,,,,,,,,TNF-α,Monocytes,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,Female,,,Intracutaneously,,Peptide
101,,,,,,,,,,Tumor antigen,Yes,,,,6.0,10000000.0,,,75.0,Months,Dead,2.0,HLA-A24,Bladder cancer,,,,,,,,,Monocytes,Surgery,Complete response,,,,,Not significant,Female,,,Subcutaneously,IV,Peptide
102,,,,,,,,,,Tumor antigen,Yes,,,,18.0,10000000.0,,,65.0,Months,Live,8.0,HLA-A24,Bladder cancer,,,,,,,,,Monocytes,Surgery,Partial Response,,,,,Not significant,Male,,,Subcutaneously,IV,Peptide
103,,,,,,,,,,Tumor antigen,Yes,,,,6.0,10000000.0,,,64.0,Months,Live,5.0,HLA-A24,Bladder cancer,,,,,,,,,Monocytes,Radiotherapy,Partial Response,,,,,Not significant,Male,,,Subcutaneously,IV,Peptide
104,,,,,,,,,,Tumor antigen,Yes,,,,6.0,10000000.0,,,56.0,Months,Live,2.0,HLA-A24,Bladder cancer,,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Subcutaneously,IV,Peptide
105,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Progressive Disease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
106,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
107,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
108,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Progressive Disease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
109,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
110,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
111,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Stable Desease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
112,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
113,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Progressive Disease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
114,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Stable Desease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
115,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Stable Desease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
116,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Stable Desease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
117,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
118,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
119,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
120,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
121,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
122,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Progressive Disease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
123,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Progressive Disease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
124,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
125,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
126,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Progressive Disease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
127,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Stable Desease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
128,Control antigen,Yes,,,,,,,KLH,,,,,,4.0,,,,50.0,,,,,Breast cancer,,,,,,,,,Monocytes,,,Increase,,,CEA,,Female,,,Intralymphatically,IV,Lysate
129,,,,,,,,,Flt3L,Tumor antigen,Yes,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,,Abnormal,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Progressive Disease,,,,,Not significant,Female,,,Intravenously,Metastatic,Peptide
130,,,,,,,,,Flt3L,,,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,Abnormal,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Progressive Disease,,,,,Not significant,,,,Intravenously,Metastatic,Peptide
131,,,,,,,,,Flt3L,,,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Lung cancer,,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Stable Desease,,,,,Not significant,Female,,,Intravenously,Metastatic,Peptide
132,,,,,,,,,Flt3L,Tumor antigen,Yes,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,,,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Progressive Disease,,,,,Not significant,,,,Intravenously,Metastatic,Peptide
133,,,,,,,,,Flt3L,Tumor antigen,Yes,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Complete response,,,,,Not significant,Female,,,Intravenously,Metastatic,Peptide
134,,,,,,,,,Flt3L,,,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,Abnormal,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Progressive Disease,,,,,Not significant,,,,Intravenously,Metastatic,Peptide
135,,,,,,,,,Flt3L,Tumor antigen,Yes,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,Abnormal,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Progressive Disease,,,,,Not significant,,,,Intravenously,Metastatic,Peptide
136,,,,,,,,,Flt3L,Tumor antigen,Yes,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,,,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Stable Desease,,,,,Not significant,Male,,,Intravenously,Metastatic,Peptide
137,,,,,,,,,Flt3L,Tumor antigen,Yes,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,Abnormal,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Progressive Disease,,,,,Not significant,Male,,,Intravenously,Metastatic,Peptide
138,,,,,,,,,Flt3L,Tumor antigen,Yes,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,Abnormal,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Progressive Disease,,,,,Not significant,,,,Intravenously,Metastatic,Peptide
139,,,,,,,,,Flt3L,Tumor antigen,Yes,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,,Abnormal,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Complete response,,,,,Not significant,,,,Intravenously,Metastatic,Peptide
140,,,,,,,,,Flt3L,,,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,Abnormal,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Partial Response,,,,,Not significant,Male,,,Intravenously,Metastatic,Peptide
141,Tumor antigen,Yes,,,,,,,KLH,,,,,,3.0,1000000.0,,,40.0,,,,,Melanoma,Normal,,,,,,,GM-CSF,Monocytes,Immunotherapy,Progressive Disease,,,,,,Female,,,Intradermal,IV,Lysate
142,,,,,,,,,,,,,,,,1000000.0,,,63.0,,,,,Melanoma,,,,,,,,,,,Partial Response,,,,,,Female,,,,,
143,,,,,,,,,,,,,,,,1000000.0,,,65.0,,,,,Melanoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
144,,,,,,,,,,,,,,,,1000000.0,,,55.0,,,,,Melanoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
145,Tumor antigen,Yes,,,,,,,,,,,,,,1000000.0,,,66.0,,,,,Melanoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
146,,,,,,,,,,,,,,,,10000000.0,,,50.0,,,,,Rectum cancer,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,,
147,,,,,,,,,,,,,,,,10000000.0,,,69.0,,,,,Melanoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
148,,,,,,,,,,,,,,10000000.0,,,,,73.0,,,,,Melanoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
149,,,,,,,,,,,,,,,,10000000.0,,,41.0,,,,,Melanoma,,,,,,,,,,Immunotherapy,Stable Desease,,,,,,Male,,,,,
150,,,,,Tumor antigen,Yes,,,,,,,,,,10000000.0,,,40.0,,,,,Melanoma,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,,,
151,,,,,,,,,,,,,,,,10000000.0,,,47.0,,,,,Rectum cancer,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,Male,,,,,
152,,,,,,,,,,,,,,,,100000000.0,,,49.0,,,,,Melanoma,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,,,
153,,,,,Tumor antigen,Yes,,,,,,,,,,100000000.0,,,66.0,,,,,Melanoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
154,,,,,Tumor antigen,Yes,,,,,,,,,,100000000.0,,,36.0,,,,,Stomach cancer,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,Female,,,,,
155,Tumor antigen,Yes,,,,,,,,,,,,,,52000000.0,,,50.0,,,,HLA-A24,,,,,,,,,,,Surgery,Progressive Disease,,,,,None,Female,,,,,
156,Tumor antigen,Yes,,,,,,,,,,,,,,27000000.0,,,54.0,,,,HLA-A24,,,,,,,,,,,Surgery,Progressive Disease,,,,,Not significant,Male,,,,,
157,Tumor antigen,Yes,,,,,,,,,,,,,,36000000.0,,,39.0,,,,HLA-A24,,,,,,,,,,,Surgery,Stable Desease,,,,,Not significant,Male,,,,,
158,,,,,,,,,,,,,,,13.0,171.7,,,53.0,Months,Dead,21.5,,,Normal,,,,,,,,,,Partial Response,,,,,Not significant,Male,,,Intravenously,,Lysate
159,,,,,,,,,,,,,,,,,,,68.0,,,,,,,,,,,,,,,,,,,,,,Male,,,,,
160,Tumor antigen,Yes,,,,,,,,Tumor antigen,Yes,,,,3.0,29.1,,,57.0,Months,Dead,4.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,Intravenously,,Lysate
161,Tumor antigen,Yes,,,,,,,,,,,,,8.0,70.4,,,70.0,Months,Dead,42.0,,,,,,,,,,,,,Stable Desease,,,,,None,Female,,,Intravenously,,Lysate
162,Tumor antigen,Yes,,,,,,,,,,,,,12.0,61.9,,,52.0,Months,Dead,25.0,,,,,,,,,,,,Immunotherapy,Stable Desease,,,,,None,Male,,,Intravenously,,Lysate
163,,,,,,,,,,,,,,,,,,,29.0,,,,,,,,,,,,,,,,,,,,,,Female,,,,,
164,Tumor antigen,Yes,,,,,,,,Tumor antigen,Yes,,,,3.0,18.7,,,60.0,Months,Dead,10.4,,,,,,,,,,,,,Progressive Disease,,,,,None,Female,,,Intravenously,,Co-culture
165,,,,,,,,,KLH,Control antigen,Yes,,,,,,,,56.0,,,,,Renal cancer,Normal,,,,,,,,Monocytes,,,,,,,,Male,,,,,
166,Tumor antigen,Yes,,,,,,,KLH,Tumor antigen,Yes,,,,6.0,52.4,,,56.0,Months,Dead,13.5,,Renal cancer,Normal,,,,,,,,Monocytes,,Stable Desease,,,,,,Female,,,Intravenously,,Co-culture
167,,,,,,,,,,Control antigen,Yes,,,,,,,,57.0,,,,,,,,,,,,,,,,,,,,,,Male,,,,,
168,Tumor antigen,Yes,,,,,,,,Tumor antigen,Yes,,,,7.0,76.0,,,59.0,Months,Dead,32.9,,,,,,,,,,,,,Complete response,,,,,None,Male,,,Intravenously,,Lysate
169,Tumor antigen,Yes,,,,,,,,Tumor antigen,Yes,,,,3.0,46.6,,,57.0,Months,Dead,4.0,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Female,,,Intravenously,,Co-culture
170,Tumor antigen,Yes,,,,,,,,Tumor antigen,Yes,,,,4.0,49.0,,,59.0,Months,Dead,8.8,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,Intravenously,,Co-culture
171,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,3.0,39.0,,,51.0,Days,Dead,,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,Intravenously,,Co-culture
172,Tumor antigen,Yes,,,,,,,,Tumor antigen,Yes,,,,6.0,70.9,,,51.0,Months,Dead,5.0,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,None,Female,,,Intravenously,,Co-culture
173,Tumor antigen,Yes,,,,,,,,,,,,,4.0,30.9,,,52.0,Months,Dead,30.0,,,,,,,,,,,,Immunotherapy,Stable Desease,,,,,,Male,,,Intravenously,,Co-culture
174,,,,,,,,,,Tumor antigen,Yes,,,,,,,,49.0,,,,,,,,,,,,,,,,,,,,,,Female,,,,,
175,Tumor antigen,Yes,,,,,,,,Tumor antigen,Yes,,,,6.0,52.0,,,54.0,Months,Dead,8.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,Intravenously,,Co-culture
176,Tumor antigen,Yes,,,,,,,,,,,,,3.0,32.0,,,57.0,,,,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Female,,,Intravenously,,Co-culture
177,Tumor antigen,Yes,,,,,,,,,,,,,3.0,33.0,,,63.0,,,,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,None,Female,,,Intravenously,,Co-culture
178,,,,,,,,,,,,,,,,,,,49.0,,,,,,,,,,,,,,,,,,,,,,Male,,,,,
179,Tumor antigen,Yes,,,,,,,,,,,,,3.0,31.0,,,71.0,Months,Dead,7.0,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,Intradermal,,Co-culture
180,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,4.0,47.0,,,46.0,,,,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,Intravenously,,Co-culture
181,Tumor antigen,Yes,,,,,,,,Tumor antigen,Yes,,,,3.0,29.0,,,55.0,Months,Dead,5.0,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,Intravenously,,Co-culture
182,Tumor antigen,Yes,,,,,,,,,,,,,3.0,12.5,,,52.0,Months,Dead,5.0,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,None,Male,,,Intradermal,,Co-culture
183,,,,,,,,,,Control antigen,Yes,,,,,,,,63.0,,,,,,,,,,,,,,,,,,,,,,Male,,,,,
184,Tumor antigen,Yes,,,,,,,,,,,,,3.0,9.7,,,53.0,,,,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,Intradermal,,Co-culture
185,Tumor antigen,Yes,,,,,,,,Tumor antigen,Yes,,,,3.0,9.7,,,55.0,,,,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,Intravenously,,Co-culture
186,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,3.0,8.3,,,57.0,Months,Dead,26.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,Intradermal,,Co-culture
187,,,,,,,,,,,,,,,,,,,66.0,,,,,,,,,,,,,,,,,,,,,,Male,,,,,
188,Tumor antigen,Yes,,,,,,,,,,,,,6.0,42.8,,,62.0,Months,Dead,24.0,,,,,,,,,,,,Immunotherapy,Stable Desease,,,,,,Female,,,Intradermal,,Co-culture
189,Tumor antigen,Yes,,,,,,,,,,,,,3.0,11.1,,,62.0,Months,Dead,23.5,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,Intradermal,,Co-culture
190,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,3.0,11.0,,,61.0,Months,Dead,23.3,,,,,,,,,,,,Immunotherapy,Complete response,,,,,,Male,,,Intradermal,,Lysate
191,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,3.0,13.9,,,63.0,Months,Dead,5.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,Intradermal,,Lysate
192,Tumor antigen,Yes,,,,,,,KLH,Control antigen,Yes,,,,3.0,7.65,,,56.0,Months,Dead,23.0,,Renal cancer,Normal,,,,,,,,Monocytes,,Progressive Disease,,,,,,Male,,,Intradermal,,Lysate
193,Tumor antigen,No,,,,,,,None,,,,,,,27000000.0,,,54.0,,,,HLA-A24,Rectum cancer,,,,,,,,,,Surgery,Progressive Disease,,,,,Not significant,Female,,,,,
194,Tumor antigen,Yes,,,,,,,None,,,,,,,53000000.0,,,64.0,,,,HLA-11,Colon cancer,,,,,,,,,,Surgery,Progressive Disease,,,,,Not significant,Female,,,,,
195,Tumor antigen,Yes,,,,,,,None,,,,,,,160000000.0,,,61.0,,,,HLA-24,Colon cancer,,,,,,,,,,Surgery,,,,,,None,Female,,,,,
196,Tumor antigen,Yes,,,,,,,None,,,,,,,110000000.0,,,28.0,,,,HLA-A2,Colon cancer,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
197,Tumor antigen,Yes,,,,,,,None,,,,,,,120000000.0,,,33.0,,,,HLA-A2,Stomach cancer,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
198,Tumor antigen,Yes,,,,,,,None,Tumor antigen,Yes,,,,,77000000.0,,,69.0,,,,HLA-A2,Lung cancer,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
199,Tumor antigen,Yes,,,,,,,None,Tumor antigen,No,,,,,85000000.0,,,57.0,,,,HLA-24,Rectum cancer,,,,,,,,,,Surgery,Stable Desease,,,,,Not significant,Female,,,,,
200,Tumor antigen,Yes,,,,,,,None,,,,,,,65000000.0,,,56.0,,,,HLA-A2,Rectum cancer,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
201,Tumor antigen,Yes,,,,,,,None,,,,,,,130000000.0,,,52.0,,,,HLA-24,Lung cancer,,,,,,,,,,Surgery,Stable Desease,,,,,Not significant,Female,,,,,
202,Tumor antigen,Yes,,,,,,,None,,,,,,,120000000.0,,,42.0,,,,HLA-24,Colon cancer,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
203,Tumor antigen,No,,,Tumor antigen,Not done,,,,,,,,,2.0,1000000.0,,,50.0,,,,HLA-A2,Breast cancer,Normal,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,None,Female,,,Subcutaneously,I,Expression vector
204,Tumor antigen,Yes,,,Tumor antigen,Yes,109.0,16.0,,,,,,,3.0,1000000.0,,,48.0,,,,HLA-A2,Breast cancer,Normal,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,,Female,,,Subcutaneously,I,Expression vector
205,Tumor antigen,Yes,,,Tumor antigen,Yes,37.0,225.0,,,,,,,3.0,1000000.0,,,66.0,,,,HLA-A2,Breast cancer,Normal,,,,,,,,Monocytes,Surgery,Stable Desease,,,,,,Female,,,Subcutaneously,I,Expression vector
206,Tumor antigen,Yes,,,Tumor antigen,Yes,16.0,154.0,,,,,,,3.0,1000000.0,,,55.0,,,,HLA-A2,Breast cancer,Normal,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,,Female,,,Subcutaneously,I,Expression vector
207,Tumor antigen,Yes,,,Tumor antigen,Yes,266.0,874.0,,,,,,,3.0,1000000.0,,,76.0,,,,HLA-A2,Pancreatic cancer,Normal,,,,,,,,Monocytes,,Progressive Disease,,,,,,Female,,,Subcutaneously,I,Expression vector
208,Tumor antigen,Yes,,,Tumor antigen,Yes,41.0,85.0,,,,,,,3.0,1000000.0,,,38.0,,,,HLA-A2,Breast cancer,Normal,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,,Female,,,Subcutaneously,I,Expression vector
209,Tumor antigen,Yes,,,Tumor antigen,Yes,804.0,1002.0,,,,,,,2.0,1000000.0,,,72.0,,,,HLA-A2,Pancreatic cancer,Normal,,,,,,,,Monocytes,,Progressive Disease,,,,,,Female,,,Subcutaneously,I,Expression vector
210,Tumor antigen,Yes,,,Tumor antigen,Yes,1.0,10.0,,,,,,,3.0,1000000.0,,,66.0,,,,HLA-A2,Hepatocellular carcinoma,Normal,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,,Male,,,Subcutaneously,I,Expression vector
211,Tumor antigen,Yes,,,Tumor antigen,Yes,249.0,260.0,,,,,,,3.0,1000000.0,,,46.0,,,,HLA-A2,Breast cancer,Normal,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,,Female,,,Subcutaneously,I,Expression vector
212,Tumor antigen,Yes,,,Tumor antigen,Yes,87.0,1.0,,,,,,,3.0,1000000.0,,,45.0,,,,HLA-A2,Breast cancer,Normal,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,,Female,,,Subcutaneously,I,Expression vector
213,,,,,Tumor antigen,Yes,,,,,,,,,,,,,69.0,,,,,,,,,,,,,,,,,,,,,,Male,,,,,
214,,,,,Tumor antigen,No,,,,,,,,,,,,,59.0,,,,,,,,,,,,,,,,,,,,,,Female,,,,,
215,,,,,Tumor antigen,No,,,,,,,,,,,,,61.0,,,,,,,,,,,,,,,,,,,,,,Male,,,,,
216,,,,,Tumor antigen,No,,,,,,,,,,,,,64.0,,,,,,,,,,,,,,,,,,,,,,Female,,,,,
217,,,,,Tumor antigen,Yes,,,,,,,,,,,,,61.0,,,,,,,,,,,,,,,,,,,,,,Male,,,,,
218,Tumor antigen,No,,,,,,,,,,,,,,10000000.0,,,47.0,Days,Dead,3.75,HLA-A2,Pancreatic cancer,Normal,,,,,,,,Monocytes,Chemotherapy,,,,,,Not significant,,,None,Intradermal,,RNA
219,,,,,,,,,,,,,,,,10000000.0,,,73.0,Days,Dead,3.75,HLA-A2,Pancreatic cancer,Normal,,,,,,,,Monocytes,Chemotherapy,,,,,,Not significant,,,Immunotherapy,Intradermal,,RNA
220,Tumor antigen,Yes,,,,,,,,,,,,,,10000000.0,,,53.0,Days,Dead,3.75,HLA-A2,Pancreatic cancer,Normal,,,,,,,,Monocytes,Chemotherapy,,,,,,Not significant,,,Immunotherapy,Intradermal,,RNA
221,Tumor antigen,No,,,,,,,,Tumor antigen,No,,,,4.0,5000000.0,,,42.0,,,,HLA-A1,Hepatocellular carcinoma,Abnormal,,,,,,,,Monocytes,,Progressive Disease,,,,,Not significant,Male,Caucasoid,,Intradermal,IV,Co-culture
222,Tumor antigen,Yes,,,,,,,,,,,,,4.0,10000000.0,,,53.0,Years,Live,3.0,HLA-A30,Hepatocellular carcinoma,Abnormal,,,,,,,,Monocytes,,Stable Desease,,,,,Not significant,Male,Caucasoid,,Intradermal,IV,RNA
223,,,,,,,,,,,,,,,2.0,10000000.0,,,46.0,Weeks,Dead,73.0,,Glioblastoma,,,,,,,,,,,Stable Desease,,,,,Not significant,,,,Intradermal,,
224,,,,,,,,,,,,,,,2.0,17000000.0,,,40.0,Weeks,Dead,216.0,,Glioma,,,,,,,,,,,Stable Desease,,,,,,Female,,,Intradermal,,
225,,,,,,,,,,,,,,,4.0,42400000.0,,,53.0,Weeks,Dead,100.0,,Glioblastoma,,,,,,,,,,,Partial Response,,,,,,Female,,,Intradermal,,
226,,,,,,,,,,,,,,,1.0,12600000.0,,,47.0,Weeks,Dead,188.0,,Glioma,,,,,,,,,,,Stable Desease,,,,,,Female,,,Intradermal,,
227,,,,,,,,,,,,,,,2.0,64000000.0,,,60.0,Weeks,Dead,63.0,,Glioblastoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,Intradermal,,
228,,,,,,,,,,,,,,,10.0,137200000.0,,,65.0,Weeks,Dead,308.0,,Glioblastoma,,,,,,,,,,,Partial Response,,,,,Not significant,Female,,,Intradermal,,
229,,,,,,,,,,,,,,,3.0,46000000.0,,,69.0,Weeks,Dead,52.0,,Glioblastoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,Intradermal,,
230,,,,,,,,,,,,,,,6.0,37500000.0,,,20.0,Weeks,Dead,60.0,,Glioblastoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,Intradermal,,
231,,,,,,,,,,,,,,,4.0,28200000.0,,,34.0,Weeks,Dead,98.0,,Prostate cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,Intradermal,,
232,,,,,,,,,,,,,,,3.0,20600000.0,,,27.0,Weeks,Dead,564.0,,Glioblastoma,,,,,,,,,,,Progressive Disease,,,,,,Female,,,Intradermal,,
233,Control antigen,Yes,5.0,7.0,,,,,,,,,,,,,,,62.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,Co-culture
234,Control antigen,Yes,13.0,16.0,,,,,,,,,,,,,,,75.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,Co-culture
235,Control antigen,Yes,5.0,4.0,,,,,,,,,,,,,,,58.0,,,,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,Co-culture
236,Control antigen,Yes,12.0,16.0,,,,,,,,,,,,,,,75.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,Lysate
237,Control antigen,Yes,34.0,28.0,,,,,,,,,,,,,,,78.0,,,,,,,,,,,,,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,,Lysate
238,Control antigen,Yes,8.0,8.0,,,,,,,,,,,,,,,46.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,Co-culture
239,Control antigen,Yes,17.0,48.0,,,,,,,,,,,,,,,60.0,,,,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,,,Lysate
240,Control antigen,Yes,9.0,9.0,,,,,,,,,,,,,,,48.0,,,,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,Co-culture
241,Control antigen,Yes,16.0,12.0,,,,,,,,,,,,,,,59.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,Co-culture
242,Control antigen,Yes,6.0,20.0,,,,,,,,,,,,,,,62.0,,,,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,Co-culture
243,Control antigen,Yes,14.0,6.0,,,,,,,,,,,,,,,42.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,Co-culture
244,Control antigen,Yes,6.0,7.0,,,,,,,,,,,,,,,62.0,,,,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,Lysate
245,,,,,,,,,,,,,,1000000.0,4.0,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,Decrease,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
246,,,,,,,,,,,,,,1000000.0,4.0,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,Decrease,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
247,,,,,,,,,,,,,,1000000.0,4.0,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,Decrease,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
248,,,,,,,,,,,,,,30000000.0,,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,Decrease,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
249,,,,,,,,,,,,,,1000000.0,4.0,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,Decrease,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
250,,,,,,,,,,,,,,30000000.0,,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,Decrease,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
251,,,,,,,,,,,,,,30000000.0,,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,Decrease,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
252,,,,,,,,,,,,,,30000000.0,,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,Decrease,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
253,,,,,,,,,,,,,,30000000.0,,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,Decrease,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
254,,,,,,,,,,Control antigen,Yes,,,10000000.0,4.0,,70.0,35.0,57.0,Days,Dead,477.0,,Colon cancer,,,,,,,,,,,Progressive Disease,Increase,,,CEA,Not significant,Male,,,Intravenously,Metastatic,RNA
255,,,,,,,,,,Control antigen,Yes,,,10000000.0,4.0,,70.0,35.0,57.0,,,,,Colon cancer,,,,,,,,,,,Progressive Disease,Increase,,,CEA,Not significant,Male,,Immunotherapy,Intravenously,Metastatic,RNA
256,Tumor antigen,Yes,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
257,Control antigen,Yes,,,,,,,,Control antigen,Yes,,,10000000.0,4.0,,70.0,35.0,57.0,,,,,Breast cancer,,,,,,,,,,,Stable Desease,Increase,,,CEA,Not significant,Female,,,Intravenously,Metastatic,RNA
258,Control antigen,Yes,,,,,,,,Control antigen,Yes,,,10000000.0,4.0,,70.0,35.0,57.0,,,,,Colon cancer,,,,,,,,,,,,Decrease,,,CA-125,Not significant,,,,Intravenously,Metastatic,RNA
259,Control antigen,Yes,,,,,,,,Control antigen,Yes,,,10000000.0,4.0,,70.0,35.0,57.0,,,,,,,,,,,,,,,,Stable Desease,Increase,,,CEA,Not significant,Male,,,Intravenously,Metastatic,RNA
260,,,,,,,,,,Control antigen,Yes,,,10000000.0,4.0,,70.0,35.0,57.0,Days,Dead,477.0,,,,,,,,,,,,,Progressive Disease,Increase,,,CEA,Not significant,Female,,,Intravenously,Metastatic,RNA
261,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,10000000.0,4.0,,70.0,35.0,57.0,Days,Dead,477.0,,,,,,,,,,,,,Progressive Disease,Increase,,,CEA,Not significant,Female,,,Intravenously,Metastatic,RNA
262,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
263,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,,,,Intravenously,,
264,Control antigen,Yes,,,,,,,,Control antigen,Yes,,,10000000.0,4.0,,70.0,35.0,57.0,Days,Dead,477.0,,,,,,,,,,,,,Stable Desease,Increase,,,CEA,Not significant,,,Immunotherapy,Intravenously,Metastatic,RNA
265,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Female,,,Intravenously,,
266,Tumor antigen,Yes,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Female,,,Intravenously,,
267,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,10000000.0,4.0,,70.0,35.0,57.0,Days,Dead,477.0,,,,,,,,,,,,,,Increase,,,CEA,Not significant,Male,,,Intravenously,Metastatic,RNA
268,Tumor antigen,Yes,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
269,,,,,,,,,,Control antigen,Yes,,,10000000.0,4.0,,70.0,35.0,57.0,,,,,,,,,,,,,,,,Progressive Disease,Increase,,,CEA,Not significant,Male,,,Intravenously,Metastatic,RNA
270,Control antigen,Yes,,,,,,,,Control antigen,Yes,,,10000000.0,4.0,,70.0,35.0,57.0,,,,,,,,,,,,,,,,Progressive Disease,Decrease,,,CA-125,Not significant,,,,Intravenously,Metastatic,RNA
271,Control antigen,Yes,,,,,,,,Control antigen,Yes,,,10000000.0,4.0,,70.0,35.0,57.0,Days,Dead,477.0,,,,,,,,,,,,,,Increase,,,CEA,Not significant,Female,,,Intravenously,Metastatic,RNA
272,,,,,,,,,,Control antigen,Yes,,,10000000.0,4.0,,70.0,35.0,57.0,Days,Dead,477.0,,Breast cancer,,,,,,,,,,,Progressive Disease,Decrease,,,CA-125,Not significant,Male,,,Intravenously,Metastatic,RNA
273,Control antigen,Yes,,,,,,,,Control antigen,Yes,,,10000000.0,4.0,,70.0,35.0,57.0,,,,,Colon cancer,,,,,,,,,,,,Increase,,,CEA,Not significant,Female,,,Intravenously,Metastatic,RNA
274,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
275,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Female,,,Intravenously,,
276,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
277,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Female,,,Intravenously,,
278,Tumor antigen,Yes,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
279,Tumor antigen,Yes,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
280,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Female,,,Intravenously,,
281,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,,,,,,,,,,,,,,,,,Not significant,,,,Intravenously,,
282,Tumor antigen,Yes,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Female,,,Intravenously,,
283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
284,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,Peptide
285,,,,,,,,,Flt3L,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,Peptide
286,,,,,,,,,Flt3L,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,Peptide
287,,,,,,,,,Flt3L,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,Peptide
288,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
289,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
290,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
291,,,,,,,,,Flt3L,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
292,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
293,,,,,,,,,Flt3L,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
294,,,,,,,,,Flt3L,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
295,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
296,,,,,Tumor antigen,Yes,,,Flt3L,,,23600000.0,6.5,13400000.0,6.0,,74.0,32.0,57.0,Months,Live,6.2,HLA-A1,Melanoma,,1.0,1.0,,,,,,Monocytes,,Stable Desease,,,,,,Female,,Immunotherapy,Subcutaneously,IV,Peptide
297,,,,,Tumor antigen,Yes,,,,,,23600000.0,6.5,13400000.0,6.0,,74.0,32.0,57.0,Months,Live,6.2,HLA-A1,Melanoma,,1.0,1.0,,,,,,Monocytes,,Stable Desease,,,,,,Female,,Immunotherapy,Subcutaneously,IV,Peptide
298,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
300,,,,,,,,,Flt3L,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
301,,,,,Tumor antigen,Yes,,,Flt3L,,,23600000.0,6.5,13400000.0,6.0,,74.0,32.0,57.0,Months,Live,6.2,HLA-A1,Melanoma,,1.0,1.0,,,,,,Monocytes,,Partial Response,,,,,,Female,,Immunotherapy,Subcutaneously,IV,Peptide
302,,,,,,,,,Flt3L,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
303,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
304,,,,,,,,,Flt3L,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
306,,,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,23600000.0,6.5,13400000.0,6.0,,74.0,32.0,57.0,Months,Live,6.2,HLA-A1,Melanoma,,1.0,1.0,,,,,,Monocytes,,Partial Response,,,,,,Female,,Immunotherapy,Subcutaneously,IV,Peptide
307,,,,,,,,,Flt3L,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
308,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
309,,,,,,,,,Flt3L,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
310,Tumor antigen,Yes,,,,,,,,,,,,,5.0,,,,69.0,Months,Dead,4.0,,Thyroid Cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
311,Tumor antigen,Yes,,,,,,,,,,,,,4.0,,75.0,18.0,49.0,Months,Dead,4.0,,Pancreatic cancer,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intralymphatically,IV,Lysate
312,Tumor antigen,Yes,,,,,,,,,,,,,4.0,,75.0,18.0,50.0,Months,Dead,3.0,,Pancreatic cancer,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intralymphatically,IV,Lysate
313,Tumor antigen,Yes,,,,,,,,,,,,,10.0,,75.0,18.0,42.0,Months,Dead,18.0,,Hepatocellular carcinoma,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intralymphatically,IV,Lysate
314,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,,10.0,,75.0,18.0,57.0,Months,Dead,9.0,,Thyroid Cancer,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,Increase,,,PSA,Not significant,Male,,Immunotherapy,Intralymphatically,IV,Lysate
315,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,,8.0,,75.0,18.0,55.0,Months,Dead,6.0,,Hepatocellular carcinoma,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intralymphatically,IV,Lysate
316,Tumor antigen,Yes,,,,,,,,,,,,,10.0,,75.0,18.0,62.0,Months,Live,22.0,,Hepatocellular carcinoma,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,,,,,Not significant,Female,,Immunotherapy,Intralymphatically,IV,Lysate
317,Tumor antigen,Yes,,,,,,,,,,,,,4.0,,75.0,18.0,52.0,Months,Dead,4.0,,Pancreatic cancer,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intralymphatically,IV,Lysate
318,Tumor antigen,Yes,,,,,,,,,,,,,10.0,,75.0,18.0,41.0,Months,Dead,9.0,,Cholangiocellular carcinoma,,,,,,60.0,,TNF-α,Monocytes,Chemotherapy,Stable Desease,Increase,,,PSA,Not significant,Male,,Immunotherapy,Intralymphatically,IV,Lysate
319,Tumor antigen,Yes,,,,,,,,,,,,,7.0,,75.0,18.0,59.0,Months,Dead,7.0,,Pancreatic cancer,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intralymphatically,IV,Lysate
320,Tumor antigen,Yes,,,,,,,,,,,,,5.0,,75.0,18.0,60.0,Months,Dead,4.0,,Pancreatic cancer,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,Increase,,,PSA,Not significant,Male,,Immunotherapy,Intralymphatically,IV,Lysate
321,Tumor antigen,Yes,,,,,,,,,,,,,10.0,,75.0,18.0,75.0,Months,Dead,12.0,,Pancreatic cancer,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,Increase,,,PSA,Not significant,Male,,Immunotherapy,Intralymphatically,IV,Lysate
322,Tumor antigen,Yes,,,,,,,,,,,,,4.0,,75.0,18.0,51.0,Months,Dead,10.0,,Pancreatic cancer,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intralymphatically,IV,Lysate
323,Tumor antigen,Yes,,,,,,,,,,,,,6.0,,75.0,18.0,60.0,Months,Dead,6.0,,Pancreatic cancer,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,,,,,Not significant,Female,,Immunotherapy,Intralymphatically,IV,Lysate
324,Tumor antigen,Yes,,,,,,,,,,,,,6.0,,75.0,18.0,63.0,Months,Dead,5.0,,Hepatocellular carcinoma,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,Increase,,,PSA,Not significant,Male,,Immunotherapy,Intralymphatically,IV,Lysate
325,Tumor antigen,Yes,,,,,,,,,,,,,10.0,,75.0,18.0,61.0,Months,Dead,24.0,,Thyroid Cancer,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,Increase,,,PSA,Not significant,Male,,Immunotherapy,Intralymphatically,IV,Lysate
326,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,,4.0,,75.0,18.0,66.0,Months,Dead,4.0,,Pancreatic cancer,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,Increase,,,PSA,Not significant,Male,,Immunotherapy,Intralymphatically,IV,Lysate
327,Tumor antigen,Yes,,,,,,,,,,,,,4.0,,75.0,18.0,71.0,Months,Dead,3.0,,Hepatocellular carcinoma,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,Increase,,,PSA,Not significant,Male,,Immunotherapy,Intralymphatically,IV,Lysate
328,Tumor antigen,Yes,,,,,,,,,,,,,10.0,,75.0,18.0,44.0,Months,Dead,9.0,,Hepatocellular carcinoma,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,,,,,Not significant,Female,,Immunotherapy,Intralymphatically,IV,Lysate
329,Tumor antigen,Yes,,,,,,,,,,,,,10.0,,75.0,18.0,31.0,Months,Dead,32.0,,Thyroid Cancer,,,,,,60.0,,TNF-α,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intralymphatically,IV,Lysate
330,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
331,Tumor antigen,No,,,,,,,,,,,,,4.0,5.2,,,64.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Radiotherapy,Stable Desease,Decrease,3797.0,6446.0,AFP,,Male,,,,,
332,Tumor antigen,Yes,,,,,,,,,,,,,12.0,18100000.0,,,48.0,,,,,Cholangiocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
333,Tumor antigen,Yes,,,,,,,,,,,,,5.0,7900000.0,,,70.0,,,,,Hepatocellular carcinoma,,,,,,,,,,,Stable Desease,Decrease,14.8,113.3,HPV16/18 E7,,Male,,,,,
334,Tumor antigen,Yes,,,,,,,,,,,,,4.0,5700000.0,,,65.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Progressive Disease,Decrease,5576.0,10154.0,AFP,,Male,,,,,
335,Tumor antigen,Yes,,,,,,,,,,,,,8.0,6300000.0,,,54.0,,,,,Hepatocellular carcinoma,,,,,,,,,,,Stable Desease,Decrease,10.0,125.8,HPV16/18 E7,,Male,,,,,
336,Tumor antigen,Yes,,,,,,,,,,,,,4.0,7800000.0,,,65.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Chemotherapy,Progressive Disease,Decrease,5.3,7.1,AFP,,Male,,,,,
337,Tumor antigen,Yes,,,,,,,,,,,,,12.0,21400000.0,,,63.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Partial Response,Decrease,50.7,78.2,AFP,,Male,,,,,
338,Tumor antigen,Yes,,,,,,,,,,,,,8.0,21300000.0,,,83.0,,,,,Cholangiocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,Decrease,116.3,121.7,CA-19,,Female,,,,,
339,Tumor antigen,Yes,,,,,,,,,,,,,4.0,29400000.0,,,75.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Radiotherapy,Stable Desease,Decrease,128.0,94.0,AFP,,Female,,,,,
340,Tumor antigen,Yes,,,,,,,,,,,,,8.0,30300000.0,,,63.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
341,Tumor antigen,No,,,,,,,,,,,,,14.0,900000.0,,,53.0,Months,Dead,19.0,,,,,,,,,,,,Surgery,Partial Response,,,,,,Female,,,,,
342,,,,,,,,,,,,,,,9.0,900000.0,,,60.0,Months,Dead,8.0,,,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
343,Tumor antigen,Yes,,1.0,,,,,,,,,,,3.0,900000.0,,,50.0,Days,Dead,1.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
344,Tumor antigen,Yes,,,,,,,,,,,,,10.0,900000.0,,,37.0,Months,Dead,10.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
345,Tumor antigen,Yes,,,,,,,,,,,,,36.0,900000.0,,,39.0,Months,Dead,55.0,,,,,,,,,,,,Surgery,Complete response,,,,,,Male,,,,,
346,Tumor antigen,Yes,,1.0,,,,,,,,,,,6.0,5000000.0,,,47.0,Months,Dead,3.5,,Melanoma,,2.0,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Female,,Radiotherapy,Intradermal,IV,Co-culture
347,,,,,,,,,,,,,,,1.0,,,,49.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
348,,,,,,,,,,,,,,,3.0,5000000.0,,,51.0,Months,Dead,3.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
349,,,,,,,,,,,,,,,1.0,5000000.0,,,67.0,Months,Dead,1.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
350,Tumor antigen,Yes,,7.5,,,,,,,,,,,5.0,5000000.0,,,64.0,Months,Dead,5.5,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
351,Tumor antigen,Yes,,5.8,,,,,,,,,,,19.0,5000000.0,,,21.0,Months,Dead,21.0,,,,,,,,,,,,,Partial Response,,,,,,Male,,,,,
352,,,,,,,,,,,,,,,1.0,,,,49.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
353,Tumor antigen,Yes,,4.0,,,,,,,,5000000.0,900000.0,,6.0,900000.0,,,66.0,Months,Dead,5.0,,Melanoma,,2.0,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intradermal,IV,Co-culture
354,Tumor antigen,Yes,,41.0,,,,,,,,,,,30.0,5000000.0,,,24.0,Months,Dead,44.0,,,,,,,,,,,,Surgery,Complete response,,,,,,Female,,,,,
355,Tumor antigen,Yes,,7.0,,,,,,,,,,,28.0,5000000.0,,,49.0,Months,Dead,38.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
356,Tumor antigen,Yes,,3.0,,,,,,,,,,,3.0,900000.0,,,27.0,Months,Dead,10.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
357,Tumor antigen,Yes,,,,,,,,,,5000000.0,900000.0,,6.0,900000.0,,,31.0,Months,Dead,6.5,,Melanoma,,2.0,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,Radiotherapy,Intradermal,IV,Co-culture
358,,,,,Tumor antigen,Yes,8.0,81.0,,Tumor antigen,Yes,,,,3.0,10000000.0,,,55.0,Months,Live,29.0,,,,,,1.0,,,,,,,,,,,,,Male,,Surgery,,,
359,,,,,Tumor antigen,Yes,12.0,25.0,,,,,,10000000.0,3.0,,,,40.0,Months,Dead,11.1,,,,,,1.0,,,,,,,,,,,,,Male,,Immunotherapy,Intravenously,,
360,,,,,Tumor antigen,Yes,2.0,32.0,,,,,,10000000.0,3.0,,,,50.0,Months,Dead,44.0,,,,,,1.0,,,,,,,,,,,,,Male,,Immunotherapy,,,
361,,,,,Tumor antigen,Yes,13.0,12.0,,,,,,,3.0,30000000.0,,,65.0,Months,Dead,28.7,,,,,,1.0,,,,,,,,,,,,,Male,,Immunotherapy,,,
362,,,,,,,,,,,,,,10000000.0,3.0,,,,73.0,Months,Dead,13.0,,,,,,1.0,,,,,,,,,,,,,Male,,Immunotherapy,,,
363,,,,,Tumor antigen,Yes,11.0,89.0,,,,,,30000000.0,3.0,,,,41.0,Months,Dead,26.5,,,,,,1.0,,,,,,,,,,,,,Male,,,,,
364,,,,,,,,,,,,,,10000000.0,3.0,,,,59.0,Months,Dead,5.5,,,,,,1.0,,,,,,,,,,,,,Male,,,,,
365,,,,,Tumor antigen,Yes,13.0,86.0,,,,,,10000000.0,3.0,,,,74.0,Months,Dead,17.9,,,,,,1.0,,,,,,,,,,,,,Female,,Immunotherapy,,,
366,,,,,,,,,,,,,,10000000.0,3.0,,,,83.0,Months,Dead,5.0,,,,,,1.0,,,,,,,,,,,,,Male,,Immunotherapy,,,
367,,,,,,,,,,,,,,10000000.0,3.0,,,,50.0,Months,Dead,12.4,,,,,,1.0,,,,,,,,,,,,,Male,,Immunotherapy,,,
368,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surgery,,,,,,,,,,,IV,
369,,,,,,,,,,,,,,,,,,,,Months,Dead,24.0,,,,,,,,,,,,Surgery,,,,,,,,,,,III,
370,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surgery,,,,,,,,,,,IV,
371,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surgery,,,,,,,,,,,IV,
372,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surgery,,,,,,,,,,,IV,
373,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surgery,,,,,,,,,,,IV,
374,,,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,,,100000.0,3.0,,79.0,39.0,60.0,Months,Dead,18.0,HLA-A*0201,Melanoma,,,,,,70.0,,,Monocytes,Chemotherapy,,,,,,,,,,Intravenously,III,Peptide
375,,,,,,,,,,,,,,,,,,,,Months,Dead,24.0,,,,,,,,,,,,Surgery,,,,,,,,,,,III,
376,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surgery,,,,,,,,,,,IV,
377,,,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,,,100000.0,3.0,,79.0,39.0,60.0,Months,Dead,18.0,HLA-A*0201,Melanoma,,,,,,70.0,,,Monocytes,Chemotherapy,,,,,,,Male,,,Intravenously,III,Peptide
378,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surgery,,,,,,,,,,,III,
379,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surgery,,,,,,,,,,,IV,
380,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surgery,,,,,,,,,,,IV,
381,,,,,,,,,,,,,,,,,,,,Months,Dead,24.0,,,,,,,,,,,,Surgery,,,,,,,,,,,III,
382,,,,,,,,,,,,,,,,,,,,Months,Dead,24.0,,,,,,,,,,,,Surgery,,,,,,,,,,,III,
383,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surgery,,,,,,,,,,,IV,
384,,,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,,,100000.0,3.0,,79.0,39.0,60.0,Months,Dead,18.0,HLA-A*0201,Melanoma,,,,,,70.0,,,Monocytes,Chemotherapy,,,,,,,,,,Intravenously,III,Peptide
385,,,,,,,,,,,,,,,,,,,,Months,Dead,24.0,,,,,,,,,,,,Surgery,,,,,,,,,,,III,
386,Tumor antigen,Yes,,,,,,,,,,,,,,,,,47.0,,,,,,,,,,,,,,,Immunotherapy,Partial Response,,,,,,Female,,,,II,
387,Tumor antigen,Yes,,,,,,,,,,,,,,,,,52.0,,,,,,,,,,,,,,,Chemotherapy,Partial Response,,,,,,Female,,,,I,
388,Tumor antigen,Yes,,,,,,,,,,,,,,,,,64.0,,,,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,I,
389,Tumor antigen,Yes,,,,,,,,,,,,,,,,,62.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,II,
390,Tumor antigen,Yes,,,,,,,,,,,,,,,,,62.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,Male,,,,I,
391,Tumor antigen,Yes,,,,,,,,,,,,,,,,,65.0,,,,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,IV,
392,,,,,,,,,,,,,,,,,,,74.0,,,,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,II,
393,Tumor antigen,Yes,,,,,,,,,,,,,,,,,57.0,,,,,,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,I,
394,Tumor antigen,Yes,,,,,,,,,,,,,,,,,47.0,,,,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,II,
395,Tumor antigen,Yes,,,,,,,,,,,,,,,,,69.0,,,,,,,,,,,,,,,Chemotherapy,Partial Response,,,,,,Female,,,,III,
396,,,,,,,,,,,,,,,10.0,,,,77.0,Months,Live,10.0,,Pancreatic cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
397,,,,,,,,,,,,,,,4.0,,,,55.0,Months,Dead,4.0,,Hepatocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
398,,,,,,,,,,,,,,,9.0,,,,73.0,Months,Dead,7.0,,Hepatocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
399,,,,,,,,,,,,,,,10.0,,,,57.0,Months,Dead,14.0,,Glioma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
400,,,,,,,,,,,,,,,10.0,,,,26.0,Months,Dead,14.0,,Thyroid Cancer,,,,,,,,,,,Partial Response,,,,,,Female,,,,,
401,,,,,,,,,,,,,,,10.0,,,,77.0,Months,Live,10.0,,Pancreatic cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
402,,,,,,,,,,,,,,,4.0,,,,55.0,Months,Dead,4.0,,Hepatocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
403,,,,,,,,,,,,,,,9.0,,,,73.0,Months,Dead,7.0,,Hepatocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
404,,,,,,,,,,,,,,,10.0,,,,57.0,Months,Dead,14.0,,Glioma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
405,,,,,,,,,,,,,,,10.0,,,,26.0,Months,Dead,14.0,,Thyroid Cancer,,,,,,,,,,,Partial Response,,,,,,Female,,,,,
406,,,,,,,,,,,,,,,10.0,,,,77.0,Months,Live,10.0,,Pancreatic cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
407,,,,,,,,,,,,,,,4.0,,,,55.0,Months,Dead,4.0,,Hepatocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
408,,,,,,,,,,,,,,,9.0,,,,73.0,Months,Dead,7.0,,Hepatocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
409,,,,,,,,,,,,,,,10.0,,,,57.0,Months,Dead,14.0,,Glioma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
410,,,,,,,,,,,,,,,10.0,,,,26.0,Months,Dead,14.0,,Thyroid Cancer,,,,,,,,,,,Partial Response,,,,,,Female,,,,,
411,,,,,,,,,,,,,,,10.0,,,,77.0,Months,Live,10.0,,Pancreatic cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
412,,,,,,,,,,,,,,,4.0,,,,55.0,Months,Dead,4.0,,Hepatocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
413,Tumor antigen,No,,,Tumor antigen,No,,,,,,,,0.05,8.0,,,,50.0,Months,Dead,3.0,,,,,,1.0,,,,,,,Partial Response,,,,,,Male,,,,,
414,Tumor antigen,Yes,,,,,,,,,,,,0.02,5.0,,,,67.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Male,,,,,
415,Tumor antigen,No,,,Tumor antigen,No,,,,,,,,0.02,3.0,,,,66.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Male,,,,,
416,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,0.05,8.0,,,,43.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Male,,,,,
417,Tumor antigen,No,,,Tumor antigen,Yes,,,,,,,,0.02,8.0,,,,41.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,None,Female,,,,,
418,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,0.02,3.0,,,,37.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Female,,,,,
419,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,0.05,5.0,,,,35.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Female,,,,,
420,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,0.07,4.0,,,,57.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Female,,,,,
421,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,0.07,8.0,,,,40.0,Months,Dead,40.0,,,,,,1.0,,,,,,,Complete response,,,,,None,Male,,,,,
422,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,0.09,8.0,,,,62.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Male,,,,,
423,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,0.09,8.0,,,,75.0,Months,Dead,8.0,,,,,,1.0,,,,,,,Partial Response,,,,,,Female,,,,,
424,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,0.11,6.0,,,,52.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,None,Female,,,,,
425,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,0.11,7.0,,,,48.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,None,Female,,,,,
426,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,0.07,8.0,,,,45.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Female,,,,,
427,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,0.07,5.0,,,,72.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Male,,,,,
428,Tumor antigen,Yes,,,Tumor antigen,No,,,,,,,,0.07,8.0,,,,44.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,None,Male,,,,,
429,Tumor antigen,Yes,,,Tumor antigen,No,,,,,,,,0.07,8.0,,,,63.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,None,Male,,,,,
430,Tumor antigen,Yes,,,Tumor antigen,No,,,,,,,,0.07,5.0,,,,71.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Male,,,,,
431,Tumor antigen,Yes,,,Tumor antigen,No,,,,,,,,0.07,5.0,,,,31.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Female,,,,,
432,Tumor antigen,Yes,,,Tumor antigen,No,,,,,,,,0.07,5.0,,,,33.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Male,,,,,
433,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,0.07,8.0,,,,60.0,Months,Dead,2.0,,,,,,1.0,,,,,,,Stable Desease,,,,,None,Male,,,,,
434,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,0.07,8.0,,,,39.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Female,,,,,
435,,,,,,,,,,Tumor antigen,No,,,,1.0,,,,60.0,,,,,Prostate cancer,,,,,,,,,,Hormonal therapy,Not evaluable,,,,,,,,,,,
436,,,,,,,,,KLH,Tumor antigen,No,,,5000000.0,6.0,15000000.0,,18.0,58.0,,,,HLA-A2,Prostate cancer,,1.0,,,,,,,Monocytes,Chemotherapy,Stable Desease,Increase,,,PSA,Not significant,,,,Subcutaneously,Metastatic,Peptide
437,,,,,,,,,,Tumor antigen,Yes,,,,6.0,,,,72.0,,,,,Prostate cancer,,,,,,,,,,Immunotherapy,Stable Desease,,,,,,,,,,,
438,,,,,,,,,,Tumor antigen,Yes,,,,6.0,,,,52.0,,,,,Prostate cancer,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,,,,,,
439,,,,,Control antigen,Yes,,,KLH,Tumor antigen,No,,,5000000.0,6.0,15000000.0,,18.0,57.0,,,,HLA-A2,Prostate cancer,,1.0,,,,,,,Monocytes,Chemotherapy,Stable Desease,Increase,,,PSA,Not significant,,,,Subcutaneously,Metastatic,Peptide
440,,,,,,,,,,Tumor antigen,Yes,,,,6.0,,,,40.0,,,,,Breast cancer,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
441,,,,,,,,,,Tumor antigen,Yes,,,,3.0,,,,52.0,,,,,Breast cancer,,,,,,,,,,Chemotherapy,Partial Response,,,,,,,,,,,
442,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
443,Control antigen,Yes,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,,,,,,Not significant,,,,Intravenously,,Protein
444,Control antigen,Yes,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,,Decrease,,,PSA,Not significant,,,,Intravenously,,Protein
445,Control antigen,Yes,,,Tumor antigen,Yes,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,,,,Intravenously,,Protein
446,Control antigen,Yes,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,,,,Intravenously,,Protein
447,Control antigen,Yes,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,,,,,,Not significant,,,,Intravenously,,Protein
448,Control antigen,Yes,,,Tumor antigen,Yes,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,,,,,,Not significant,,,,Intravenously,,Protein
449,Control antigen,Yes,,,Tumor antigen,Yes,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,,,,Intravenously,,Protein
450,Control antigen,Yes,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,,Decrease,,,PSA,Not significant,,,,Intravenously,,Protein
451,Control antigen,Yes,,,Tumor antigen,Yes,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,,,,,,Not significant,,,,Intravenously,,Protein
452,Control antigen,Yes,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,,,,,,Not significant,,,,Intravenously,,Protein
453,Control antigen,Yes,,,Tumor antigen,Yes,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,,,,Intravenously,,Protein
454,Control antigen,Yes,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,,,,,,Not significant,,,,Intravenously,,Protein
455,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
456,Control antigen,Yes,,,Tumor antigen,Yes,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,,Prostate cancer,,,,,,,,,Monocytes,Surgery,,Decrease,,,PSA,Not significant,,,,Intravenously,,Protein
457,Control antigen,Yes,,,Tumor antigen,Yes,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,,,,,,Not significant,,,,Intravenously,,Protein
458,Control antigen,Yes,,,Tumor antigen,Yes,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,,Decrease,,,PSA,Not significant,,,,Intravenously,,Protein
459,Control antigen,Yes,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,Intravenously,,Protein
460,Control antigen,Yes,,,Tumor antigen,Yes,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,,Prostate cancer,,,,,,,,,Monocytes,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,Intravenously,,Protein
461,Control antigen,Yes,,,Tumor antigen,Yes,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,,Prostate cancer,,,,,,,,,Monocytes,Surgery,,,,,,Not significant,,,,Intravenously,,Protein
462,Control antigen,Yes,,,Tumor antigen,Yes,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,,Prostate cancer,,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,,,,Intravenously,,Protein
463,Control antigen,Yes,,,Tumor antigen,Yes,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,,Prostate cancer,,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,,,,Intravenously,,Protein
464,Control antigen,Yes,,,Tumor antigen,Yes,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,,,,,,Not significant,,,,Intravenously,,Protein
465,Control antigen,Yes,,,Tumor antigen,Yes,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,Days,Live,,,Prostate cancer,,,,,,,,,Monocytes,Surgery,,Decrease,,,PSA,Not significant,,,,Intravenously,,Protein
466,,,,,,,,,,Tumor antigen,Yes,,,5000000.0,10.0,,,,46.0,Months,Live,24.0,HLA-A2,Breast cancer,,,,,,,,,,Chemotherapy,Stable Desease,,,,,Not significant,,,Immunotherapy,Subcutaneously,Metastatic,Peptide
467,,,,,,,,,,,,,,,8.0,,,,65.0,Months,Live,7.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
468,,,,,,,,,,,,,,,8.0,,,,49.0,Months,Live,17.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
469,,,,,,,,,,,,,,,7.0,,,,51.0,Months,Live,41.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
470,,,,,,,,,,,,,,,10.0,,,,41.0,Months,Live,15.0,,,,,,,,,,,,Chemotherapy,Partial Response,,,,,,,,,,,
471,,,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,,,5000000.0,10.0,,,,62.0,Months,Live,14.0,HLA-A2,Breast cancer,,,,,,,,,,Chemotherapy,Stable Desease,,,,,Not significant,,,Immunotherapy,Subcutaneously,Metastatic,Peptide
472,,,,,,,,,,,,,,,,100000000.0,,,,Weeks,Live,8.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
473,,,,,,,,,,,,,,,,100000000.0,,,,Weeks,Live,8.0,,,,,,,,,,,,Chemotherapy,Not applicable,,,,,,,,,,,
474,,,,,,,,,,,,,,,,100000000.0,,,,Weeks,Live,4.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
475,,,,,,,,,,,,,,,,100000000.0,,,,Weeks,Live,5.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
476,,,,,,,,,,,,,,,,100000000.0,,,,Weeks,Live,4.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
477,,,,,,,,,,,,,,,,200000000.0,,,,Weeks,Live,14.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
478,,,,,,,,,,,,,,,,2000000000.0,,,,Weeks,Live,75.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
479,,,,,,,,,,,,,,,,2100000000.0,,,,Weeks,Live,18.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
480,,,,,,,,,,,,,,,,2000000000.0,,,,Weeks,Live,23.0,,,,,,,,,,,,Chemotherapy,Partial Response,,,,,,,,,,,
481,,,,,,,,,,,,,,,,2000000000.0,,,,Weeks,Live,9.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
482,,,,,,,,,,,,,,,,3000000000.0,,,,Weeks,Live,94.0,,,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,,,,,,
483,,,,,,,,,,,,,,,,3000000000.0,,,,Weeks,Dead,4.0,,,,,,,,,,,,Chemotherapy,Death,,,,,,,,,,,
484,,,,,,,,,,,,,,,,2000000000.0,,,,Weeks,Live,8.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
485,,,,,,,,,,,,,,,,2000000000.0,,,,Weeks,Live,77.0,,,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,,,,,,
486,,,,,,,,,,,,,,,,3000000000.0,,,,Weeks,Live,12.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
487,,,,,,,,,,,,,,,,3000000000.0,,,,Weeks,Dead,7.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
488,,,,,,,,,,,,,,,,2000000000.0,,,,Weeks,Live,20.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
489,,,,,,,,,,,,,,,,100000000.0,,,,Weeks,Live,8.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
490,,,,,,,,,,,,,,,,100000000.0,,,,Weeks,Live,8.0,,,,,,,,,,,,Chemotherapy,Not applicable,,,,,,,,,,,
491,Tumor antigen,Yes,,,,,,,,Tumor antigen,Yes,,,,,,,,70.0,Months,Live,21.0,,,,,,,,,,,,Hormonal therapy,Partial Response,Decrease,,,PSA,,,,,,Metastatic,
492,,,,,,,,,,,,,,,,,,,82.0,Months,Dead,8.0,,,,,,,,,,,,Radiotherapy,Partial Response,Decrease,,,PSA,,,,,,Metastatic,
493,,,,,,,,,,,,,,,,,,,64.0,Months,Dead,1.0,,,,,,,,,,,,Hormonal therapy,Progressive Disease,Decrease,,,PSA,,,,,,Metastatic,
494,,,,,,,,,,,,,,,,,,,45.0,Months,Live,21.0,,,,,,,,,,,,Hormonal therapy,Progressive Disease,Decrease,,,PSA,,,,,,Metastatic,
495,,,,,,,,,,,,,,,,,,,65.0,Months,Live,24.0,,,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,PSA,,,,,,Metastatic,
496,,,,,,,,,,,,,,,,,,,51.0,Months,Live,21.0,,,,,,,,,,,,Hormonal therapy,Progressive Disease,Decrease,,,PSA,,,,,,Metastatic,
497,,,,,,,,,,,,,,,,,,,50.0,Months,Dead,11.0,,,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,PSA,,,,,,Recurrent,
498,,,,,,,,,,,,,,,,,,,72.0,Months,Dead,16.0,,,,,,,,,,,,Surgery,Stable Desease,Decrease,,,PSA,,,,,,Metastatic,
499,,,,,,,,,,,,,,,,,,,72.0,Months,Live,18.0,,,,,,,,,,,,Hormonal therapy,Stable Desease,Decrease,,,PSA,,,,,,Recurrent,
500,,,,,,,,,,,,,,,,,,,64.0,Months,Live,18.0,,,,,,,,,,,,Hormonal therapy,Stable Desease,Decrease,,,PSA,,,,,,Recurrent,
501,,,,,,,,,,,,,,,,,,,59.0,Months,Live,17.0,,,,,,,,,,,,Surgery,Stable Desease,Decrease,,,PSA,,,,,,Metastatic,
502,Tumor antigen,Yes,,,,,,,,Tumor antigen,Yes,,,,,,,,70.0,Months,Live,21.0,,,,,,,,,,,,Hormonal therapy,Partial Response,Decrease,,,PSA,,,,,,Metastatic,
503,Tumor antigen,Yes,,,,,,,,,,,,,7.0,5000000.0,,,,Months,Live,31.0,,Thyroid Cancer,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,,,,,IV,
504,Tumor antigen,Yes,,,,,,,,,,,,,3.0,1000000.0,,,,Months,Dead,73.0,,Thyroid Cancer,,,,,,,,,,Chemotherapy,,,,,,,,,,,IV,
505,Tumor antigen,Yes,,,,,,,,,,,,,8.0,5000000.0,,,,Months,Live,38.0,,Renal cancer,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,,
506,Tumor antigen,Yes,,,,,,,,,,,,,7.0,5000000.0,,,,Months,Dead,26.0,,Solid malignancies,,,,,,,,,,Chemotherapy,,,,,,,,,,,IV,
507,Tumor antigen,Yes,,,,,,,,,,,,,8.0,5000000.0,,,,Months,Dead,46.0,,Renal cancer,,,,,,,,,,Surgery,,,,,,,,,,,IV,
508,Tumor antigen,Yes,,,,,,,,,,,,,9.0,5000000.0,,,,Months,Live,23.0,,Thyroid Cancer,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,IV,
509,Tumor antigen,Yes,,,,,,,,,,,,,5.0,5000000.0,,,,Months,Dead,22.0,,Pancreatic cancer,,,,,,,,,,Chemotherapy,,,,,,,,,,,IV,
510,Tumor antigen,Yes,,,,,,,,,,,,,4.0,5000000.0,,,,Months,Dead,18.0,,Glioblastoma,,,,,,,,,,Surgery,,,,,,,,,,,IV,
511,Tumor antigen,Yes,,,,,,,,,,,,,8.0,5000000.0,,,,Months,Dead,14.0,,Glioblastoma,,,,,,,,,,Surgery,,,,,,,,,,,IV,
512,Tumor antigen,Yes,,,,,,,,,,,,,5.0,5000000.0,,,,Months,Dead,7.0,,Prostate cancer,,,,,,,,,,Surgery,,,,,,,,,,,IV,
513,Tumor antigen,Yes,,,,,,,,,,,,,5.0,5.0,,,,Months,Dead,30.0,,Glioblastoma,,,,,,,,,,Surgery,,,,,,,,,,,IV,
514,Tumor antigen,Yes,,,,,,,,,,,,,5.0,5000000.0,,,,Months,Dead,33.0,,Prostate cancer,,,,,,,,,,Surgery,,,,,,,,,,,IV,
515,Tumor antigen,Yes,,,,,,,,,,,,,4.0,5000000.0,,,,Months,Dead,11.0,,Melanoma,,,,,,,,,,Radiotherapy,,,,,,,,,,,IV,
516,Tumor antigen,Yes,,,,,,,,,,,,,8.0,5000000.0,,,,Months,Dead,49.0,,Melanoma,,,,,,,,,,Surgery,,,,,,,,,,,IV,
517,Tumor antigen,Yes,,,,,,,,,,,,,5.0,5000000.0,,,,Months,Live,10.0,,Renal cancer,,,,,,,,,,Surgery,,,,,,,,,,,IV,
518,Tumor antigen,Yes,,,,,,,,,,,,,3.0,5000000.0,,,,Months,Dead,21.0,,Solid malignancies,,,,,,,,,,Surgery,,,,,,,,,,,IV,
519,Tumor antigen,Yes,,,,,,,,,,,,,4.0,5000000.0,,,,Months,Live,24.0,,Thyroid Cancer,,,,,,,,,,Chemotherapy,,,,,,,,,,,IV,
520,Tumor antigen,Yes,,,,,,,,,,,,,12.0,5000000.0,,,,Months,Live,279.0,,Hepatocellular carcinoma,,,,,,,,,,Surgery,,,,,,,,,,,IV,
521,Tumor antigen,Yes,,,Tumor antigen,Yes,,2.15,,Tumor antigen,Yes,,,,5.0,15000000.0,72.0,23.0,37.0,Months,Dead,30.0,,Cervical cancer,,,,,,,,,Monocytes,Surgery,Not evaluable,Yes,,,HPV16/18 E7,Not significant,,Caucasoid,,Subcutaneously,I,Protein
522,Tumor antigen,Yes,,,Tumor antigen,Yes,,2.15,,Tumor antigen,Yes,,,,5.0,15000000.0,72.0,23.0,31.0,Months,Dead,31.0,,Cervical cancer,,,,,,,,,Monocytes,Surgery,Not evaluable,Yes,,,HPV16/18 E7,Not significant,,Caucasoid,,Subcutaneously,I,Protein
523,Tumor antigen,Yes,,,Tumor antigen,Yes,,2.15,,Tumor antigen,Yes,,,,5.0,15000000.0,72.0,23.0,32.0,Months,Dead,30.0,,Cervical cancer,,,,,,,,,Monocytes,Surgery,Not evaluable,Yes,,,HPV16/18 E7,Not significant,,Caucasoid,,Subcutaneously,I,Protein
524,Tumor antigen,Yes,,,Tumor antigen,Yes,,2.15,,Tumor antigen,Yes,,,,5.0,15000000.0,72.0,23.0,34.0,Months,Dead,26.0,,Cervical cancer,,,,,,,,,Monocytes,Surgery,Not evaluable,Yes,,,HPV16/18 E7,Not significant,,Caucasoid,,Subcutaneously,I,Protein
525,,,,,,,,,,,,,,,5.0,,,,43.0,Months,Dead,26.0,,Nasopharyngeal carcinoma,,,,,,,,,,Surgery,Not evaluable,,,,,,,Caucasoid,,,I,
526,Tumor antigen,Yes,,,Tumor antigen,Yes,,2.15,,Tumor antigen,Yes,,,,5.0,15000000.0,72.0,23.0,72.0,Months,Dead,25.0,,Cervical cancer,,,,,,,,,Monocytes,Surgery,Not evaluable,Yes,,,HPV16/18 E7,Not significant,,Caucasoid,,Subcutaneously,I,Protein
527,,,,,,,,,,,,,,,5.0,,,,39.0,Months,Dead,25.0,,Nasopharyngeal carcinoma,,,,,,,,,,Surgery,Not evaluable,,,,,,,Caucasoid,,,I,
528,Tumor antigen,Yes,,,Tumor antigen,Yes,,2.15,,,,,,,5.0,15000000.0,72.0,23.0,23.0,Months,Dead,20.0,,Cervical cancer,,,,,,,,,Monocytes,Surgery,Not evaluable,Yes,,,HPV16/18 E7,Not significant,,Caucasoid,,Subcutaneously,I,Protein
529,Tumor antigen,Yes,,,Tumor antigen,Yes,,2.15,,Tumor antigen,Yes,,,,5.0,15000000.0,72.0,23.0,32.0,Months,Dead,19.0,,Cervical cancer,,,,,,,,,Monocytes,Surgery,Not evaluable,Yes,,,HPV16/18 E7,Not significant,,Caucasoid,,Subcutaneously,I,Protein
530,Tumor antigen,Yes,,,Tumor antigen,Yes,,2.15,,Tumor antigen,Yes,,,,5.0,15000000.0,72.0,23.0,23.0,Months,Dead,17.0,,Cervical cancer,,,,,,,,,Monocytes,Surgery,Not evaluable,Yes,,,HPV16/18 E7,Not significant,,Caucasoid,,Subcutaneously,I,Protein
531,,,,,,,,,,Control antigen,Yes,,,,,,,,55.0,,,,HLA-A24,Solid malignancies,,1.0,1.0,,,,,,Monocytes,Surgery,,Decrease,,,CEA,,Female,,Immunotherapy,,Metastatic,Peptide
532,,,,,,,,,,,,,,,,,,,56.0,,,,,Rectum cancer,,,,,,,,,,Surgery,,,,,,,Male,,,,,
533,,,,,,,,,,,,,,,,,,,52.0,,,,,Lung cancer,,,,,,,,,,Surgery,,,,,,,Female,,,,,
534,,,,,,,,,,,,,,,,,,,28.0,,,,,Colon cancer,,,,,,,,,,Surgery,,,,,,,Female,,,,,
535,,,,,,,,,,,,,,,,,,,42.0,,,,,Colon cancer,,,,,,,,,,Surgery,,,,,,,Female,,,,,
536,,,,,,,,,,,,,,,,,,,33.0,,,,,Stomach cancer,,,,,,,,,,Chemotherapy,,,,,,,Female,,,,,
537,,,,,,,,,,,,,,,,,,,60.0,,,,,Colon cancer,,,,,,,,,,Surgery,,,,,,,Female,,,,,
538,,,,,,,,,,,,,,,,,,,63.0,,,,,Colon cancer,,,,,,,,,,Surgery,,,,,,,Female,,,,,
539,,,,,,,,,,,,,,,,,,,69.0,,,,,Lung cancer,,,,,,,,,,Surgery,,,,,,,Male,,,,,
540,,,,,,,,,,,,,,,,,,,46.0,,,,,Colon cancer,,,,,,,,,,Surgery,,,,,,,Female,,,,,
541,,,,,,,,,,,,,,,,,,,53.0,,,,,Stomach cancer,,,,,,,,,,Surgery,,,,,,,Male,,,,,
542,,,,,,,,,,,,,,,,,,,65.0,,,,,Colon cancer,,,,,,,,,,Surgery,,,,,,,Female,,,,,
543,,,,,,,,,,,,,,,,,,,56.0,,,,,Lung cancer,,,,,,,,,,Surgery,,,,,,,Male,,,,,
544,,,,,Tumor antigen,Yes,,,,,,,,,10.0,,,,58.0,Months,Live,14.0,,,,,,,,,,,,Hormonal therapy,Stable Desease,,,,,,,,,,,
545,,,,,Tumor antigen,Yes,,,,,,,,,9.0,,,,47.0,Months,Dead,9.0,,,,,,,,,,,,,Stable Desease,,,,,,,,,,,
546,,,,,Tumor antigen,Yes,,,,,,,,,9.0,,,,46.0,Months,Dead,26.5,,,,,,,,,,,,Hormonal therapy,Stable Desease,,,,,,,,,,,
547,,,,,Tumor antigen,Yes,,,,,,,,,10.0,,,,64.0,Months,Dead,21.0,,,,,,,,,,,,Hormonal therapy,Stable Desease,,,,,,,,,,,
548,,,,,Tumor antigen,Yes,,,,,,,,,3010.0,,,,44.0,Months,Dead,12.5,,,,,,,,,,,,Hormonal therapy,Progressive Disease,,,,,,,,,,,
549,,,,,Tumor antigen,Yes,,,,,,,,,10.0,,,,58.0,Months,Dead,13.0,,,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,,,,,,
550,,,,,Tumor antigen,Yes,,,,,,,,,10.0,,,,74.0,Months,Live,5.5,,,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,,,,,,
551,,,,,Tumor antigen,Yes,,,,,,,,,8.0,,,,66.0,Months,Dead,21.0,,,,,,,,,,,,Chemotherapy,Partial Response,,,,,,,,,,,
552,,,,,Tumor antigen,Yes,,,,,,,,,7.0,,,,72.0,Months,Dead,4.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
553,,,,,Tumor antigen,Yes,,,,,,,,,5.0,,,,54.0,Months,Dead,2.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
554,,,,,Tumor antigen,Yes,,,,,,,,,1006.0,,,,59.0,Months,Dead,7.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
555,,,,,Tumor antigen,Yes,,,,,,,,,5.0,,,,33.0,Months,Dead,2.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
556,,,,,Tumor antigen,Yes,,,,,,,,,7.0,,,,46.0,Months,Dead,13.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
557,,,,,Tumor antigen,Yes,,,,,,,,,6.0,,,,51.0,Months,Dead,10.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
558,,,,,Tumor antigen,Yes,,,,,,,,,6.0,,,,64.0,Months,Dead,2.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
559,,,,,Tumor antigen,Yes,,,,,,,,,505.0,,,,64.0,Months,Dead,2.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
560,,,,,Tumor antigen,Yes,,,,,,,,,7.0,,,,52.0,Months,Dead,3.0,,,,,,,,,,,,Hormonal therapy,Progressive Disease,,,,,,,,,,,
561,,,,,Tumor antigen,Yes,,,,,,,,,6.0,,,,64.0,Months,Dead,21.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
562,,,,,Tumor antigen,Yes,,,,,,,,,6.0,,,,62.0,Months,Dead,9.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
563,,,,,Tumor antigen,Yes,,,,,,,,,3.0,,,,51.0,Months,Dead,1.0,,,,,,,,,,,,Hormonal therapy,Progressive Disease,,,,,,,,,,,
564,,,,,Tumor antigen,Yes,,,,,,,,,3.0,,,,61.0,Months,Dead,1.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
565,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,56.0,Months,Dead,8.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
566,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,36.0,Months,Dead,4.5,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
567,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,44.0,Months,Dead,4.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
568,,,,,Tumor antigen,Yes,,,,,,,,,3.0,,,,58.0,Months,Dead,4.0,,,,,,,,,,,,Hormonal therapy,Progressive Disease,,,,,,,,,,,
569,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,56.0,Months,Dead,1.5,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
570,,,,,,,,,,,,,,,,,,,70.0,,,,,,,,,,,,,,,Surgery,Complete response,,,,,,,,,,I,
571,,,,,,,,,,,,,,,,,,,62.0,,,,,,,,,,,,,,,Surgery,Complete response,,,,,,,,,,I,
572,,,,,,,,,,,,,,,,,,,66.0,,,,,,,,,,,,,,,Surgery,Not evaluable,,,,,,,,,,I,
573,,,,,,,,,,,,,,,,,,,65.0,,,,,,,,,,,,,,,Surgery,Not evaluable,,,,,,,,,,I,
574,,,,,,,,,,,,,,,,,,,56.0,,,,,,,,,,,,,,,Surgery,Stable Desease,,,,,,,,,,I,
575,,,,,,,,,,,,,,,,,,,60.0,,,,,,,,,,,,,,,Surgery,Not evaluable,,,,,,,,,,I,
576,,,,,,,,,,,,,,,,,,,67.0,,,,,,,,,,,,,,,Surgery,Not evaluable,,,,,,,,,,II,
577,,,,,,,,,,,,,,,,,,,59.0,,,,,,,,,,,,,,,Chemotherapy,Not evaluable,,,,,,,,,,III,
578,,,,,,,,,,,,,,,2.0,10000000.0,,,67.0,Days,Dead,,,Lung cancer,,,,,,,,,Monocytes,Chemotherapy,Progressive Disease,Decrease,,,HER-2/Neu,None,,,,Intradermal,III,Protein
579,,,,,,,,,,,,,,,2.0,10000000.0,,,51.0,Days,Dead,,,Lung cancer,,,,,,,,,Monocytes,Surgery,Progressive Disease,Decrease,,,HER-2/Neu,None,,,,Intradermal,III,Protein
580,,,,,,,,,,,,,,,,,,,48.0,,,,,,,,,,,,,,,Chemotherapy,Not evaluable,,,,,,,,,,III,
581,,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,,,,,,Chemotherapy,Not evaluable,,,,,,,,,,III,
582,,,,,Tumor antigen,No,,,,,,,,,2.0,10000000.0,,,63.0,Days,Dead,,,Lung cancer,,,,,,,,,Monocytes,Chemotherapy,Progressive Disease,Decrease,,,HER-2/Neu,None,,,,Intradermal,III,Protein
583,,,,,Tumor antigen,Yes,4.0,34.0,,,,,,,2.0,10000000.0,,,58.0,Days,Dead,,,Lung cancer,,,,,,,,,Monocytes,Chemotherapy,Stable Desease,Decrease,,,HER-2/Neu,None,,,,Intradermal,III,Protein
584,,,,,,,,,,,,,,,,,,,48.0,,,,,Ovarian cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
585,,,,,,,,,,,,,,,,,,,56.0,,,,,Bladder cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
586,,,,,,,,,,,,,,,,,,,62.0,,,,,Ovarian cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
587,,,,,,,,,,,,,,,,,,,37.0,,,,,Thyroid Cancer,,,,,,,,,,,Partial Response,,,,,,Female,,,,,
588,,,,,,,,,,,,,,,,,,,42.0,,,,,Solid malignancies,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
589,,,,,,,,,,,,,,,,,,,71.0,,,,,Breast cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
590,,,,,,,,,,,,,,,,,,,46.0,,,,,Rectum cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,
591,,,,,,,,,,,,,,,,,,,53.0,,,,,Ovarian cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
592,,,,,,,,,,,,,,,,,,,68.0,,,,,Renal cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
593,,,,,,,,,,,,,,,,,,,47.0,,,,,Cholangiocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
594,,,,,,,,,,,,,,,,,,,37.0,,,,,Renal cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
595,,,,,,,,,,,,,,,,,,,73.0,,,,,Solid malignancies,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
596,,,,,,,,,,,,,,,,,,,66.0,,,,,Pancreatic cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,
597,,,,,,,,,,,,,,,,,,,43.0,,,,,Thyroid Cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
598,,,,,,,,,,,,,,,,,,,45.0,,,,,Ovarian cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
599,Tumor antigen,No,,,,,,,,,,,,,16.0,,,,154.0,Days,Live,1370.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
600,Tumor antigen,Yes,,,,,,,,,,,,,5.0,,,,252.0,Days,Live,151.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
601,Tumor antigen,Yes,,,,,,,,,,,,,16.0,,,,372.0,Days,Live,379.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
602,Tumor antigen,Yes,,,,,,,,,,,,,9.0,,,,446.0,Days,Dead,1313.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
603,Tumor antigen,Yes,,,,,,,,,,,,,16.0,,,,568.0,Days,Dead,1174.0,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
604,Tumor antigen,Yes,,,,,,,,,,,,,16.0,,,,667.0,Days,Dead,1048.0,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
605,Tumor antigen,Yes,,,Tumor antigen,No,,,,,,,,,,,,,61.0,Months,Live,43.0,,,,,,,,,,,,,Stable Desease,,,,,,Female,,,,II,
606,Tumor antigen,No,,,Tumor antigen,Yes,,,,,,,,,,,,,55.0,Months,Dead,40.0,,,,,,,,,,,,,Partial Response,,,,,,Male,,,,I,
607,Tumor antigen,No,,,Tumor antigen,No,,,,,,,,,,,,,50.0,Months,Dead,29.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,III,
608,Tumor antigen,No,,,Tumor antigen,No,,,,,,,,,,,,,63.0,Months,Dead,43.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,III,
609,Tumor antigen,No,,,Tumor antigen,Yes,,,,,,,,,,,,,59.0,Months,Dead,10.0,,,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,I,
610,Tumor antigen,No,,,Tumor antigen,No,,,,,,,,,,,,,55.0,Months,Dead,1.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,II,
611,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,,,,,,54.0,Months,Dead,28.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,I,
612,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,,,,,,37.0,Months,Dead,1.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,III,
613,Tumor antigen,No,,,Tumor antigen,Yes,,,,,,,,,,,,,59.0,Months,Dead,1.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,III,
614,Tumor antigen,No,,,Tumor antigen,Yes,,,,,,,,,,,,,62.0,Months,Dead,24.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,I,
615,Tumor antigen,No,,,Tumor antigen,No,,,,,,,,,,,,,59.0,Months,Dead,13.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,I,
616,Tumor antigen,No,,,Tumor antigen,No,,,,,,,,,,,,,68.0,Months,Dead,10.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,I,
617,Tumor antigen,No,,,Tumor antigen,No,,,,,,,,,,,,,58.0,Months,Dead,1.0,,,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,I,
618,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,,,,,,54.0,Months,Dead,9.0,,,,,,,,,,,,,Stable Desease,,,,,,Female,,,,I,
619,Tumor antigen,No,,,Tumor antigen,Yes,,,,,,,,,,,,,66.0,Months,Dead,9.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,III,
620,,,,,,,,,,,,,,,1.0,,,,57.0,Weeks,Dead,16.0,,,,,,1.0,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
621,,,,,,,,,,,,,,,,,,,63.0,,,,,,,,,1.0,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
622,,,,,,,,,,,,,,,,,,,77.0,,,,,,,,,1.0,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
623,Tumor antigen,Yes,,,,,,,,,,,,,4.0,3e+14,,,,,,,HLA-A2,Stomach cancer,,2.0,1.0,,,,,OK-432,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,Subcutaneously,Metastatic,Peptide
624,,,,,,,,,,,,,,,,,,,,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Partial Response,Decrease,,,PSA,Not significant,,,,,,
625,,,,,,,,,,,,,,,,,,,,,,,,Hepatocellular carcinoma,,,,,,,,,,Chemotherapy,Progressive Disease,Decrease,,,PSA,Not significant,,,,,,
626,,,,,,,,,,,,,,,,,,,,,,,,Hepatocellular carcinoma,,,,,,,,,,Chemotherapy,Partial Response,Decrease,,,PSA,Not significant,,,,,,
627,Tumor antigen,Yes,,,,,,,,,,,,,4.0,3e+14,,,,,,,HLA-A2,Stomach cancer,,2.0,1.0,,,,,OK-432,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,Subcutaneously,Metastatic,Peptide
628,,,,,,,,,,,,,,,4.0,3e+14,,,,,,,HLA-A2,Stomach cancer,,2.0,1.0,,,,,OK-432,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,Subcutaneously,Metastatic,Peptide
629,,,,,,,,,,,,,,,4.0,3e+14,,,,,,,HLA-A2,Stomach cancer,,2.0,1.0,,,,,OK-432,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,Subcutaneously,Metastatic,Peptide
630,Tumor antigen,Yes,,,,,,,,,,,,,4.0,3e+14,,,,,,,HLA-A2,Stomach cancer,,2.0,1.0,,,,,OK-432,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,Subcutaneously,Metastatic,Peptide
631,Tumor antigen,Yes,,,,,,,,,,,,,4.0,3e+14,,,,,,,HLA-A2,Stomach cancer,,2.0,1.0,,,,,OK-432,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,Subcutaneously,Metastatic,Peptide
632,,,,,,,,,,,,,,,,,,,,,,,,Rectum cancer,,,,,,,,,,Surgery,Partial Response,Decrease,,,PSA,Not significant,,,,,,
633,,,,,,,,,,,,,,,,,,,,,,,,Rectum cancer,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,,,
634,,,,,,,,,,,,,,,,,,,,,,,,Rectum cancer,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,,,
635,,,,,,,,,,Tumor antigen,Yes,,,,4.0,3e+14,,,,,,,HLA-A2,Stomach cancer,,2.0,1.0,,,,,OK-432,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,Subcutaneously,Metastatic,Peptide
636,,,,,,,,,,,,,,,4.0,3e+14,,,,,,,HLA-A2,Stomach cancer,,2.0,1.0,,,,,OK-432,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,Subcutaneously,Metastatic,Peptide
637,,,,,,,,,,,,,,,4.0,3e+14,,,,,,,HLA-A2,Stomach cancer,,2.0,1.0,,,,,OK-432,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,Subcutaneously,Metastatic,Peptide
638,,,,,,,,,,,,,,,,,,,,,,,,Rectum cancer,,,,,,,,,,Surgery,Stable Desease,Decrease,,,PSA,Not significant,,,,,,
639,,,,,,,,,,,,,,,,,,,,,,,,Bladder cancer,,,,,,,,,,Surgery,Partial Response,Decrease,,,PSA,Not significant,,,,,,
640,,,,,,,,,,,,,,,,,,,,,,,,Rectum cancer,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,,,
641,Tumor antigen,Yes,,,,,,,,,,,,,4.0,3e+14,,,,,,,HLA-A2,Stomach cancer,,2.0,1.0,,,,,OK-432,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,Subcutaneously,Metastatic,Peptide
642,,,,,,,,,,,,,,,,,,,,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,,,
643,,,,,,,,,,,,,,,,,,,,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,,,
644,,,,,,,,,,,,,,,,,,,,,,,,Rectum cancer,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,,,
645,,,,,,,,,,,,,,,,,,,,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,,,
646,,,,,,,,,,,,,,,,,,,,,,,,Hepatocellular carcinoma,,,,,,,,,,Chemotherapy,Progressive Disease,Decrease,,,PSA,Not significant,,,,,,
647,,,,,,,,,,,,,,,,,,,,,,,,Bladder cancer,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,,,
648,,,,,,,,,,,,,,,,,,,,,,,,Rectum cancer,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,,,
649,,,,,,,,,,,,,,,,,,,,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,,,
650,,,,,,,,,,,,,,,,,,,,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,PSA,Not significant,,,,,,
651,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
652,,,,,,,,,,,,,,,4.0,5.0,,,42.0,Months,Dead,10.0,,,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,III,
653,,,,,,,,,,,,,,,4.0,5.0,,,57.0,Months,Dead,62.0,,,,,,,,,,,,,Not evaluable,,,,,,Female,,,,III,
654,,,,,,,,,,,,,,,4.0,5.0,,,32.0,Months,Dead,43.0,,,,,,,,,,,,,Not evaluable,,,,,,Male,,,,III,
655,,,,,,,,,,,,,,,4.0,5.0,,,17.0,Months,Dead,53.0,,,,,,,,,,,,,Not evaluable,,,,,,Female,,,,III,
656,,,,,,,,,,,,,,,4.0,10.0,,,56.0,Months,Dead,4.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,IV,
657,,,,,,,,,,,,,,,4.0,3.0,,,60.0,Months,Dead,45.0,,,,,,,,,,,,,Not evaluable,,,,,,Male,,,,III,
658,,,,,,,,,,,,,,,2.0,10.0,,,27.0,Months,Dead,1.0,,,,,,,,,,,,,Partial Response,,,,,,Male,,,,IV,
659,,,,,,,,,,,,,,,4.0,10.0,,,26.0,Months,Dead,7.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,IV,
660,,,,,,,,,,,,,,,4.0,15.0,,,42.0,Months,Dead,79.0,,,,,,,,,,,,,Not evaluable,,,,,,Female,,,,III,
661,,,,,,,,,,,,,,,4.0,15.0,,,34.0,Months,Dead,11.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,IV,
662,,,,,,,,,,,,,,,4.0,15.0,,,44.0,Months,Dead,4.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,IV,
663,,,,,,,,,,,,,,,4.0,15.0,,,56.0,Months,Dead,33.0,,,,,,,,,,,,,Not evaluable,,,,,,Male,,,,III,
664,,,,,,,,,,,,,,,4.0,20.0,,,47.0,Months,Dead,34.0,,,,,,,,,,,,,Not evaluable,,,,,,Male,,,,II,
665,,,,,,,,,,,,,,,4.0,20.0,,,30.0,Months,Dead,47.0,,,,,,,,,,,,,Not evaluable,,,,,,Male,,,,III,
666,,,,,,,,,,,,,,,4.0,20.0,,,52.0,Months,Dead,10.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,IV,
667,,,,,,,,,,,,,,,4.0,20.0,,,57.0,Months,Dead,6.0,,,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,IV,
668,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
669,,,,,,,,,,,,,,,10.0,,,,57.0,Days,Live,29.5,,,,,,,,,,,,,Stable Desease,,,,,,Male,,Immunotherapy,,,
670,,,,,Tumor antigen,Yes,,,KLH,,,,,,13.0,,79.0,38.0,79.0,Months,Dead,25.0,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Stable Desease,,,,,Not significant,Female,,Immunotherapy,,,Lysate
671,,,,,Tumor antigen,Yes,,,KLH,,,,,,10.0,,79.0,38.0,61.0,Months,Dead,7.5,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
672,,,,,Tumor antigen,Yes,,,KLH,,,,,,6.0,,79.0,38.0,60.0,Months,Dead,5.0,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
673,,,,,Tumor antigen,Yes,,,KLH,,,,,,13.0,,79.0,38.0,38.0,Months,Dead,16.5,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
674,,,,,Tumor antigen,Yes,,,KLH,,,,,,21.0,,79.0,38.0,61.0,Months,Dead,20.0,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
675,,,,,Tumor antigen,Yes,,,KLH,,,,,,13.0,,79.0,38.0,78.0,Months,Dead,11.0,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
676,,,,,Tumor antigen,Yes,,,KLH,,,,,,23.0,,79.0,38.0,66.0,Months,Dead,16.0,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Stable Desease,,,,,Not significant,Female,,Immunotherapy,,,Lysate
677,,,,,Tumor antigen,Yes,,,KLH,,,,,,6.0,,79.0,38.0,59.0,Months,Dead,6.5,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Progressive Disease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
678,,,,,Tumor antigen,Yes,,,KLH,,,,,,6.0,,79.0,38.0,60.0,Months,Dead,3.0,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Progressive Disease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
679,,,,,Tumor antigen,Yes,,,KLH,,,,,,6.0,,79.0,38.0,54.0,Months,Dead,5.0,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Progressive Disease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
680,,,,,Tumor antigen,Yes,,,KLH,,,,,,6.0,,79.0,38.0,42.0,Months,Dead,10.5,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Progressive Disease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
681,,,,,Tumor antigen,Yes,,,KLH,,,,,,6.0,,79.0,38.0,70.0,Months,Dead,4.5,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Progressive Disease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
682,,,,,Tumor antigen,Yes,,,KLH,,,,,,6.0,,79.0,38.0,59.0,Months,Dead,13.0,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Progressive Disease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
683,Tumor antigen,No,,,,,,,,Control antigen,Yes,,,,,30000000.0,,,44.0,Months,Live,41.0,,Glioblastoma,,,,,,,,,,Radiotherapy,,,,,,,Male,,,,,
684,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,,30000000.0,,,40.0,Months,Dead,12.3,,Glioblastoma,,,,,,,,,,Radiotherapy,,,,,,,Female,,,,,
685,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,,30000000.0,,,50.0,Months,Dead,17.5,,Glioblastoma,,,,,,,,,,Radiotherapy,,,,,,,Male,,,,,
686,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,,100000000.0,,,37.0,Months,Dead,15.9,,Glioblastoma,,,,,,,,,,Immunotherapy,,,,,,,Male,,,,,
687,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,,100000000.0,,,37.0,Months,Dead,6.7,,Glioblastoma,,,,,,,,,,Radiotherapy,,,,,,,Male,,,,,
688,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,,100000000.0,,,58.0,Months,Dead,20.0,,Glioblastoma,,,,,,,,,,Immunotherapy,,,,,,,Female,,,,,
689,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,,100000000.0,,,55.0,Months,Dead,19.6,,Glioblastoma,,,,,,,,,,Radiotherapy,,,,,,,Female,,,,,
690,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,,55000000.0,,,44.0,Months,Dead,40.8,,Glioblastoma,,,,,,,,,,Chemotherapy,,,,,,,Male,,,,,
691,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,,23000000.0,,,34.0,Months,Dead,65.4,,Glioblastoma,,,,,,,,,,Immunotherapy,,,,,,,Female,,,,,
692,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,,29000000.0,,,55.0,Months,Dead,25.6,,Glioblastoma,,,,,,,,,,Radiotherapy,,,,,,,Male,,,,,
693,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,,57000000.0,,,35.0,Months,Dead,28.1,,Glioblastoma,,,,,,,,,,Radiotherapy,,,,,,,Male,,,,,
694,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,,76000000.0,,,36.0,Months,Dead,46.2,,Glioblastoma,,,,,,,,,,Radiotherapy,,,,,,,Male,,,,,
695,,,,,,,,,,,,,,,,0.23,,,37.0,,,,,Renal cancer,,,,,,,,,,,,,,,,,Female,,,,III,
696,,,,,,,,,,,,,,,,5.1,,,55.0,,,,,Renal cancer,,,,,,,,,,,,,,,,,Male,,,,Metastatic,
697,,,,,,,,,,,,,,,,1.75,,,68.0,,,,,Renal cancer,,,,,,,,,,,,,,,,,Female,,,,III,
698,,,,,,,,,,,,,,,,2.6,,,56.0,,,,,Renal cancer,,,,,,,,,,,,,,,,,Male,,,,III,
699,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
700,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
701,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
702,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
703,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
704,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
705,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
706,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
707,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
708,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
709,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
710,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
711,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
712,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
713,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
714,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
715,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
716,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
717,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
718,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
719,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
720,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
721,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
722,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
723,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
724,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
725,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
726,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
727,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
728,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
729,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
730,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
731,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
732,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
733,,,,,,,,,,Tumor antigen,Yes,,,,,,,,61.0,Days,Dead,84.0,,,,,,1.0,,,,,,,Partial Response,,,,,,Male,,,,III,
734,,,,,,,,,,,,,,,,,,,66.0,Days,Dead,198.0,,,,,,2.0,,,,,,,Stable Desease,,,,,,Male,,,,III,
735,,,,,,,,,,,,,,,,,,,59.0,Days,Dead,112.0,,,,,,1.0,,,,,,,Stable Desease,,,,,,Male,,,,III,
736,,,,,,,,,,,,,,,,,,,63.0,Days,Dead,82.0,,,,,,2.0,,,,,,,Stable Desease,,,,,,Female,,,,IV,
737,,,,,,,,,,,,,,,,,,,50.0,Days,Dead,277.0,,Glioblastoma,,,,,,,,,,,Partial Response,,,,,,Female,,,,I,
738,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
739,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
740,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
741,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
742,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
743,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
744,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
745,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
746,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
747,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
748,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
749,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
750,,,,,,,,,,,,,,,4.0,2000000.0,,,64.0,,,,,Melanoma,,2.0,1.0,,,,,,,Surgery,Partial Response,,,,,Not significant,Male,,,Intravenously,,Peptide
751,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
752,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
753,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
754,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
755,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
756,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
757,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
758,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
759,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
760,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
761,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
762,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
763,,,,,,,,,,,,,,,4.0,100000.0,,,61.0,,,,,Lung cancer,,2.0,1.0,,,,,,,Surgery,Partial Response,,,,,Not significant,Male,,,Intravenously,,Peptide
764,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
765,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
766,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
767,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
768,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
769,,,,,,,,,,,,,,,4.0,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,2.0,1.0,,,,,,,Surgery,Stable Desease,,,,,Not significant,Female,,,Intravenously,,Peptide
770,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
771,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
772,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
773,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
774,,,,,,,,,,,,,,,,2000000.0,,,57.0,,,,,Renal cancer,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
775,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
776,,,,,,,,,,,,,,,4.0,100000.0,,,61.0,,,,,Lung cancer,,2.0,1.0,,,,,,,Surgery,Partial Response,,,,,Not significant,Male,,,Intravenously,,Peptide
777,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
778,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
779,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
780,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
781,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
782,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
783,,,,,,,,,,,,,,,4.0,2000000.0,,,51.0,,,,,Pancreatic cancer,,2.0,1.0,,,,,,,Immunotherapy,Not evaluable,,,,,Not significant,Male,,,Intravenously,,Peptide
784,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
785,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
786,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
787,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
788,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
789,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
790,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
791,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
792,,,,,,,,,,,,,,,4.0,100000.0,,,64.0,,,,,Melanoma,,2.0,1.0,,,,,,,Surgery,Stable Desease,Decrease,,,CEA,Not significant,Male,,,Intravenously,,Peptide
793,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
794,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
795,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
796,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
797,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
798,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
799,,,,,,,,,,,,,,,4.0,100000.0,,,61.0,,,,,Lung cancer,,2.0,1.0,,,,,,,Surgery,Partial Response,,,,,Not significant,Male,,,Intravenously,,Peptide
800,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
801,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
802,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
803,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
804,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
805,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
806,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
807,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
808,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
809,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
810,,,,,,,,,,,,,,,,2000000.0,,,57.0,,,,,Renal cancer,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
811,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
812,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
813,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
814,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
815,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
816,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
817,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
818,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
819,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
820,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
821,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
822,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
823,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
824,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
825,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
826,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
827,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
828,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
829,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
830,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
831,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
832,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
833,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
834,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
835,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
836,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
837,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
838,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
839,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
840,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
841,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
842,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
843,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
844,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
845,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
846,,,,,,,,,,,,,,,,2000000.0,,,51.0,,,,,Pancreatic cancer,,,,,,,,,,Immunotherapy,Not evaluable,,,,,,Male,,,,,
847,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
848,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
849,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
850,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
851,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
852,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
853,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
854,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
855,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
856,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
857,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
858,,,,,,,,,,,,,,,4.0,100000.0,,,61.0,,,,,Lung cancer,,2.0,1.0,,,,,,,Surgery,Partial Response,,,,,Not significant,Male,,,Intravenously,,Peptide
859,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
860,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
861,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
862,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
863,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
864,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
865,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
866,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
867,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
868,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
869,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
870,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
871,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
872,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
873,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
874,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
875,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
876,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
877,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
878,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
879,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
880,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
881,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
882,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
883,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
884,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
885,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
886,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
887,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
888,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
889,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
890,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
891,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
892,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
893,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
894,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
895,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
896,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
897,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
898,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
899,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
900,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
901,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
902,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
903,,,,,,,,,,,,,,,4.0,2000000.0,,,64.0,,,,,Melanoma,,2.0,1.0,,,,,,,Surgery,Partial Response,,,,,Not significant,Male,,,Intravenously,,Peptide
904,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
905,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
906,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
907,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
908,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
909,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
910,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
911,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
912,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
913,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
914,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
915,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
916,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
917,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
918,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
919,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
920,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
921,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
922,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
923,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
924,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
925,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
926,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
927,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
928,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
929,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
930,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
931,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
932,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
933,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
934,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
935,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
936,,,,,,,,,,,,,,,4.0,100000.0,,,61.0,,,,,Lung cancer,,2.0,1.0,,,,,,,Surgery,Partial Response,,,,,Not significant,Male,,,Intravenously,,Peptide
937,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
938,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
939,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
940,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
941,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
942,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
943,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
944,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
945,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
946,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
947,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
948,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
949,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
950,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
951,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
952,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
953,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
954,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
955,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
956,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
957,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
958,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
959,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
960,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
961,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
962,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,2.0,1.0,,,,,,,Surgery,Not evaluable,,,,,Not significant,Female,,,Intravenously,,Peptide
963,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
964,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
965,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,2.0,1.0,,,,,,,Surgery,Not evaluable,,,,,Not significant,Female,,,Intravenously,,Peptide
966,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
967,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
968,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
969,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
970,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
971,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
972,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
973,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
974,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
975,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
976,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
977,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
978,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
979,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
980,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
981,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
982,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
983,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,2.0,1.0,,,,,,,Surgery,Not evaluable,,,,,Not significant,Female,,,Intravenously,,Peptide
984,,,,,,,,,,,,,,,4.0,100000.0,,,64.0,,,,,Melanoma,,2.0,1.0,,,,,,,Surgery,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Peptide
985,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
986,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
987,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
988,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
989,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
990,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
991,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
992,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
993,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
994,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
995,,,,,,,,,,,,,,,,2000000.0,,,57.0,,,,,Renal cancer,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
996,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,2.0,1.0,,,,,,,Surgery,Not evaluable,,,,,Not significant,Female,,,Intravenously,,Peptide
997,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
998,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
999,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1000,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1001,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1002,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1003,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1004,,,,,,,,,,,,,,,,2000000.0,,,51.0,,,,,Pancreatic cancer,,,,,,,,,,Immunotherapy,Not evaluable,,,,,,Male,,,,,
1005,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1006,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1007,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1008,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1009,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1010,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1011,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1012,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1013,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1014,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1015,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1016,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1017,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1018,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1019,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1020,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1021,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1022,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1023,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1024,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1025,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1026,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1027,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1028,,,,,,,,,,,,,,,,2000000.0,,,57.0,,,,,Renal cancer,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1029,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1030,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1031,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1032,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1033,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1034,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1035,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1036,,,,,,,,,,,,,,,,2000000.0,,,57.0,,,,,Renal cancer,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1037,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1038,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1039,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1040,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1041,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1042,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1043,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1044,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1045,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1046,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1047,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1048,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1049,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1050,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Lung cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1051,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1052,Tumor antigen,Not done,,,Tumor antigen,Not done,,,,,,,,,2.0,33000000.0,,,49.0,,,,,Melanoma,,,,,,,,,,Surgery,Not applicable,,,,,Not applicable,Female,,,Subcutaneously,IV,RNA
1053,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,,4.0,22000000.0,,,81.0,,,,,Glioblastoma,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1054,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,,4.0,40000000.0,,,39.0,,,,,Glioblastoma,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1055,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,,4.0,44000000.0,,,50.0,,,,,Breast cancer,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1056,Tumor antigen,Yes,,,,,,,,,,,,,4.0,40000000.0,,,71.0,,,,,Glioblastoma,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1057,Tumor antigen,Yes,,,,,,,,,,,,,3.0,37000000.0,,,60.0,,,,,Colon cancer,,,,,,,,,,Surgery,,,,,,,Male,,,,II,
1058,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1059,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1060,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1061,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1062,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1063,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1064,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1065,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1066,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1067,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1068,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1069,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1070,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1071,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1072,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1073,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1074,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1075,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1076,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1077,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1078,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1079,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1080,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1081,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1082,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1083,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1084,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1085,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1086,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1087,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1088,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1089,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1090,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1091,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1092,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1093,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1094,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1095,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1096,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1097,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1098,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1099,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1100,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1101,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1102,,,,,,,,,,,,,,,4.0,,61.0,18.0,51.0,,,,,,,,,,,,,,,Chemotherapy,Not evaluable,,,,,,,,Chemotherapy,,III,
1103,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1104,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1105,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1106,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1107,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1108,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1109,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1110,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1111,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1112,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1113,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1114,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1115,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1116,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1117,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1118,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1119,,,,,,,,,,,,,,,4.0,,61.0,18.0,51.0,,,,,,,,,,,,,,,Chemotherapy,Not evaluable,,,,,,,,Chemotherapy,,III,
1120,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1121,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1122,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1123,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1124,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1125,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1126,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1127,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1128,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1129,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1130,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1131,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1132,,,,,,,,,,,,,,,4.0,,61.0,18.0,51.0,,,,,,,,,,,,,,,Chemotherapy,Not evaluable,,,,,,,,Chemotherapy,,III,
1133,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1134,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1135,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1136,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1137,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1138,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1139,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1140,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1141,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1142,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1143,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1144,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1145,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1146,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1147,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1148,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1149,,,,,,,,,,,,,,,4.0,,61.0,18.0,51.0,,,,,,,,,,,,,,,Chemotherapy,Not evaluable,,,,,,,,Chemotherapy,,III,
1150,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1151,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1152,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1153,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1154,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1155,,,,,,,,,,,,,,,4.0,,61.0,18.0,51.0,,,,,,,,,,,,,,,Chemotherapy,Not evaluable,,,,,,,,Chemotherapy,,III,
1156,,,,,Tumor antigen,No,,,,,,,,,2.0,50000000.0,,,62.0,,,,,Renal cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,IV,
1157,,,,,,,,,,,,,,,2.0,50000000.0,,,56.0,,,,,Renal cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,IV,
1158,,,,,,,,,,,,,,,3.0,50000000.0,,,67.0,,,,,Renal cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,IV,
1159,,,,,,,,,,,,,,,2.0,50000000.0,,,29.0,,,,,Renal cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,II,
1160,,,,,,,,,,,,,,,2.0,50000000.0,,,24.0,,,,,Renal cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,IV,
1161,,,,,,,,,,,,,,,2.0,50000000.0,,,62.0,,,,,Renal cancer,,,,,,,,,,,,,,,,,Male,,,,IV,
1162,,,,,,,,,,,,,,,2.0,50000000.0,,,43.0,,,,,Breast cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,IV,
1163,,,,,,,,,,,,,,,2.0,50000000.0,,,29.0,,,,,Breast cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,IV,
1164,,,,,,,,,,,,,,,2.0,50000000.0,,,59.0,,,,,Breast cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,III,
1165,,,,,,,,,,,,,,,2.0,50000000.0,,,66.0,,,,,Breast cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,II,
1166,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1167,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1168,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1169,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1170,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1171,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1172,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1173,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1174,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1175,,,,,,,,,,,,,,,,1000000.0,,,,,,,,Hepatocellular carcinoma,,,,,,,,Microorganisms and their fragments,Monocytes,Chemotherapy,Progressive Disease,,,,,,,,,,IV,Peptide
1176,,,,,,,,,,,,,,,,1000000.0,,,,,,,,Hepatocellular carcinoma,,,,,,,,Microorganisms and their fragments,Monocytes,Chemotherapy,Progressive Disease,,,,,,,,,,IV,Peptide
1177,,,,,,,,,,,,,,,,1000000.0,,,,,,,,Hepatocellular carcinoma,,,,,,,,Microorganisms and their fragments,Monocytes,Radiotherapy,,,,,,,,,,,IV,Peptide
1178,,,,,,,,,,,,,,,,1000000.0,,,,,,,,Hepatocellular carcinoma,,,,,,,,Microorganisms and their fragments,Monocytes,,,,,,,,,,,,IV,Peptide
1179,,,,,,,,,,,,,,,,1000000.0,,,,,,,,Hepatocellular carcinoma,,,,,,,,Microorganisms and their fragments,Monocytes,Surgery,Progressive Disease,,,,,,,,,,IV,Peptide
1180,,,,,,,,,,,,,,,,5000000.0,,,,,,,,Hepatocellular carcinoma,,,,,,,,Microorganisms and their fragments,Monocytes,Chemotherapy,Not evaluable,,,,,,,,,,IV,Peptide
1181,,,,,,,,,,,,,,,,5000000.0,,,,,,,,Hepatocellular carcinoma,,,,,,,,Microorganisms and their fragments,Monocytes,Chemotherapy,Progressive Disease,,,,,,,,,,IV,Peptide
1182,,,,,,,,,,,,,,,,5000000.0,,,,,,,,Hepatocellular carcinoma,,,,,,,,Microorganisms and their fragments,Monocytes,Chemotherapy,Progressive Disease,,,,,,,,,,IV,Peptide
1183,,,,,,,,,,,,,,,4.0,6.0,,,59.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,None,Male,,,,IV,
1184,,,,,,,,,,,,,,,4.0,6.0,,,59.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,None,Male,,,,IV,
1185,,,,,,,,,,,,,,,4.0,6.0,,,59.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,None,Male,,,,IV,
1186,,,,,,,,,,,,,,,4.0,6.0,,,59.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,None,Male,,,,IV,
1187,,,,,,,,,,,,,,,4.0,6.0,,,59.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,None,Male,,,,IV,
1188,,,,,,,,,,,,,,,4.0,6.0,,,59.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,None,Male,,,,IV,
1189,,,,,,,,,,,,,,,4.0,6.0,,,59.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,None,Male,,,,IV,
1190,,,,,,,,,,,,,,,5.0,24970000.0,,,46.0,Months,Dead,12.54,,,,,,1.0,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1191,,,,,,,,,,,,,,,5.0,24100000.0,,,47.0,Months,Dead,7.75,,,,,,1.0,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
1192,,,,,,,,,,,,,,,5.0,24970000.0,,,46.0,Months,Dead,12.54,,,,,,1.0,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1193,,,,,,,,,,,,,,,5.0,24100000.0,,,47.0,Months,Dead,7.75,,,,,,1.0,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
1194,,,,,,,,,,,,,,,5.0,24970000.0,,,46.0,Months,Dead,12.54,,,,,,1.0,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1195,,,,,,,,,,,,,,,5.0,24100000.0,,,47.0,Months,Dead,7.75,,,,,,1.0,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
1196,,,,,,,,,,,,,,,5.0,24970000.0,,,46.0,Months,Dead,12.54,,,,,,1.0,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1197,,,,,,,,,,,,,,,5.0,24100000.0,,,47.0,Months,Dead,7.75,,,,,,1.0,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
1198,,,,,,,,,,,,,,,5.0,24970000.0,,,46.0,Months,Dead,12.54,,,,,,1.0,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1199,,,,,,,,,,,,,,,5.0,24100000.0,,,47.0,Months,Dead,7.75,,,,,,1.0,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
1200,,,,,,,,,,,,,,,5.0,24970000.0,,,46.0,Months,Dead,12.54,,,,,,1.0,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1201,,,,,,,,,,,,,,,5.0,24100000.0,,,47.0,Months,Dead,7.75,,,,,,1.0,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
1202,,,,,,,,,,,,,,,5.0,24970000.0,,,46.0,Months,Dead,12.54,,,,,,1.0,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1203,,,,,,,,,,,,,,,5.0,24100000.0,,,47.0,Months,Dead,7.75,,,,,,1.0,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
1204,,,,,,,,,,,,,,,5.0,24970000.0,,,46.0,Months,Dead,12.54,,,,,,1.0,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1205,,,,,,,,,,,,,,,5.0,24100000.0,,,47.0,Months,Dead,7.75,,,,,,1.0,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
1206,,,,,,,,,,,,,,25000000.0,10.0,,,,18.0,Weeks,Dead,204.0,,Glioma,,,,,,,90.0,,,,,,,,,Not significant,Female,,,,,
1207,,,,,,,,,,,,,,11000000.0,10.0,,,,38.0,Weeks,Dead,305.0,,Glioblastoma,,,,,,,90.0,,,,,,,,,Significant,Male,,,,,
1208,,,,,,,,,,,,,,21000000.0,8.0,,,,60.0,Weeks,Dead,48.0,,Glioblastoma,,,,,,,80.0,,,,,,,,,None,Male,,,,,
1209,,,,,,,,,,,,,,25000000.0,10.0,,,,24.0,Weeks,Dead,47.0,,Glioblastoma,,,,,,,80.0,,,,,,,,,Not significant,Male,,,,,
1210,,,,,,,,,,,,,,50000000.0,10.0,,,,23.0,Weeks,Dead,286.0,,Glioblastoma,,,,,,,90.0,,,,,,,,,Not significant,Male,,,,,
1211,,,,,,,,,,,,,,58000000.0,10.0,,,,50.0,Weeks,Dead,90.0,,Glioblastoma,,,,,,,90.0,,,,,,,,,None,Female,,,,,
1212,,,,,,,,,,,,,,30000000.0,10.0,,,,61.0,Weeks,Dead,89.0,,Glioblastoma,,,,,,,90.0,,,,,,,,,None,Female,,,,,
1213,,,,,,,,,,,,,,10000000.0,10.0,,,,41.0,Weeks,Dead,281.0,,Colorectal cancer,,,,,,,80.0,,,,,,,,,Not significant,Male,,,,,
1214,,,,,,,,,,,,,,35000000.0,10.0,,,,25.0,Weeks,Dead,182.0,,Renal cancer,,,,,,,90.0,,,,,,,,,None,Female,,,,,
1215,,,,,,,,,,,,,,42000000.0,10.0,,,,45.0,Weeks,Dead,45.0,,Glioblastoma,,,,,,,90.0,,,,,,,,,Not significant,Female,,,,,
1216,,,,,,,,,,,,,,38000000.0,6.0,,,,60.0,Weeks,Dead,44.0,,Glioblastoma,,,,,,,90.0,,,,,,,,,None,Female,,,,,
1217,,,,,,,,,,,,,,25000000.0,10.0,,,,42.0,Weeks,Dead,45.0,,Renal cancer,,,,,,,70.0,,,,,,,,,Not significant,Female,,,,,
1218,,,,,,,,,,,,,,23000000.0,6.0,,,,34.0,Weeks,Dead,23.0,,Glioblastoma,,,,,,,90.0,,,,,,,,,Not significant,Female,,,,,
1219,,,,,,,,,,,,,,30000000.0,10.0,,,,55.0,Weeks,Dead,121.0,,Glioblastoma,,,,,,,70.0,,,,,,,,,Not significant,Female,,,,,
1220,,,,,,,,,,,,,,61000000.0,10.0,,,,69.0,Weeks,Dead,61.0,,Glioblastoma,,,,,,,70.0,,,,,,,,,None,Male,,,,,
1221,,,,,,,,,,,,,,61000000.0,10.0,,,,47.0,Weeks,Dead,155.0,,Glioblastoma,,,,,,,80.0,,,,,,,,,None,Male,,,,,
1222,,,,,,,,,,,,,,25000000.0,10.0,,,,18.0,Weeks,Dead,204.0,,Glioma,,,,,,,90.0,,,,,,,,,Not significant,Female,,,,,
1223,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1224,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1225,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1226,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1227,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1228,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1229,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1230,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1231,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1232,,,,,,,,,,,,,,,,,,,65.0,,,,,,,,,,,,,,,Target therapy,Progressive Disease,Increase,23.0,56.0,AFP,,Male,,,,III,
1233,,,,,,,,,,,,,,,,,,,65.0,,,,,,,,,,,,,,,Target therapy,Progressive Disease,Increase,23.0,56.0,AFP,,Male,,,,III,
1234,,,,,,,,,,,,,,,,,,,65.0,,,,,,,,,,,,,,,Target therapy,Progressive Disease,Increase,23.0,56.0,AFP,,Male,,,,III,
1235,,,,,,,,,,,,,,,,,,,65.0,,,,,,,,,,,,,,,Target therapy,Progressive Disease,Increase,23.0,56.0,AFP,,Male,,,,III,
1236,,,,,,,,,,,,,,,,,,,65.0,,,,,,,,,,,,,,,Target therapy,Progressive Disease,Increase,23.0,56.0,AFP,,Male,,,,III,
1237,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1238,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1239,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1240,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1241,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1242,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1243,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1244,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1245,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1246,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1247,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1248,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1249,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1250,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1251,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1252,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1253,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1254,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1255,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1256,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1257,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1258,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1259,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1260,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,Days,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1261,Tumor antigen,Yes,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1262,Tumor antigen,Yes,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1263,Tumor antigen,Yes,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1264,Tumor antigen,Yes,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1265,Tumor antigen,Yes,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1266,Tumor antigen,Yes,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1267,Tumor antigen,Yes,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1268,Tumor antigen,Yes,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1269,Tumor antigen,Yes,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1270,Tumor antigen,Yes,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1271,Tumor antigen,Yes,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1272,Tumor antigen,Yes,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1273,Tumor antigen,Yes,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1274,Tumor antigen,Yes,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1275,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1276,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1277,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1278,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1279,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1280,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1281,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1282,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1283,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1284,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1285,,,,,,,,,,,,,,,5.0,,,,,Months,Live,14.0,,Melanoma,,,,,,,,,Monocytes,,Stable Desease,,,,,Not significant,,,,Intravenously,,RNA
1286,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1287,,,,,,,,,,,,,,,5.0,,,,,Months,Live,14.0,,Melanoma,,,,,,,,,Monocytes,,,,,,,Not significant,,,,Intravenously,,RNA
1288,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1289,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1290,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1291,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1292,,,,,,,,,,,,,,,5.0,,,,,Months,Dead,28.0,,Melanoma,,,,,,,,,Monocytes,,,,,,,Not significant,,,,Intravenously,,RNA
1293,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1294,,,,,,,,,,,,,,,5.0,,,,46.0,Months,Dead,33.0,,,,,,,,,1.0,,,Immunotherapy,Complete response,,,,,,Male,,,,IV,
1295,,,,,,,,,,,,,,,5.0,,,,46.0,Months,Dead,33.0,,,,,,,,,1.0,,,Immunotherapy,Complete response,,,,,,Male,,,,IV,
1296,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1297,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1298,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1299,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1300,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1301,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1302,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1303,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1304,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1305,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1306,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1307,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1308,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1309,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1310,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1311,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1312,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1313,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1314,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1315,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1316,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1317,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1318,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1319,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1320,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1321,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1322,,,,,,,,,,,,,,,4.0,,,,,Months,Dead,28.0,,Melanoma,,,,,,,,,Monocytes,,,,,,,Not significant,,,,Intravenously,,RNA
1323,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1324,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1325,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1326,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1327,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1328,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1329,,,,,,,,,,,,,,,5.0,,,,46.0,Months,Dead,33.0,,,,,,,,,1.0,,,Immunotherapy,Complete response,,,,,,Male,,,,IV,
1330,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1331,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1332,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1333,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1334,,,,,,,,,,,,,,,5.0,,,,,Months,Dead,28.0,,Melanoma,,,,,,,,,Monocytes,,,,,,,Not significant,,,,Intravenously,,RNA
1335,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1336,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1337,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1338,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1339,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1340,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1341,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1342,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1343,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1344,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,14.4,,,,,,,,,1.0,,,Immunotherapy,Stable Desease,,,,,,Male,,,,IV,
1345,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1346,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1347,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1348,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1349,,,,,,,,,,,,,,,5.0,,,,,Months,Dead,28.0,,Melanoma,,,,,,,,,Monocytes,,,,,,,Not significant,,,,Intravenously,,RNA
1350,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1351,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1352,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1353,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1354,,,,,,,,,,,,,,,5.0,,,,,Months,Dead,28.0,,Melanoma,,,,,,,,,Monocytes,,Complete response,,,,,Not significant,,,,Intravenously,,RNA
1355,,,,,,,,,,,,,,,4.0,,,,,Months,Dead,28.0,,Melanoma,,,,,,,,,Monocytes,,,,,,,Not significant,,,,Intravenously,,RNA
1356,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1357,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1358,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1359,,,,,,,,,,,,,,,5.0,,,,46.0,Months,Dead,33.0,,,,,,,,,1.0,,,Immunotherapy,Complete response,,,,,,Male,,,,IV,
1360,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1361,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1362,,,,,,,,,,,,,,,5.0,,,,46.0,Months,Dead,33.0,,,,,,,,,1.0,,,Immunotherapy,Complete response,,,,,,Male,,,,IV,
1363,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1364,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1365,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1366,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1367,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1368,,,,,,,,,,,,,,,5.0,,,,,Months,Dead,28.0,,Melanoma,,,,,,,,,Monocytes,,,,,,,Not significant,,,,Intravenously,,RNA
1369,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1370,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1371,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1372,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1373,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1374,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1375,,,,,,,,,,,,,,,5.0,,,,,Months,Dead,28.0,,Melanoma,,,,,,,,,Monocytes,,,,,,,Not significant,,,,Intravenously,,RNA
1376,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1377,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1378,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1379,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1380,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1381,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1382,,,,,,,,,,,,,,,5.0,,,,46.0,Months,Dead,33.0,,,,,,,,,1.0,,,Immunotherapy,Complete response,,,,,,Male,,,,IV,
1383,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1384,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1385,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1386,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1387,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1388,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1389,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1390,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1391,,,,,,,,,,,,,,,5.0,,,,46.0,Months,Dead,33.0,,,,,,,,,1.0,,,Immunotherapy,Complete response,,,,,,Male,,,,IV,
1392,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1393,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1394,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1395,,,,,,,,,,,,,,,4.0,,,,42.0,Months,Dead,8.6,,,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1396,,,,,,,,,,,,,,,5.0,,,,46.0,Months,Dead,33.0,,,,,,,,,1.0,,,Immunotherapy,Complete response,,,,,,Male,,,,IV,
1397,,,,,,,,,,,,,,,4.0,,,,41.0,Months,Dead,9.9,,,,,,,,,2.0,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,IV,
1398,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1399,,,,,,,,,,,,,,,5.0,,,,42.0,Months,Dead,18.8,,,,,,,,,1.0,,,Surgery,Stable Desease,,,,,,Female,,,,IV,
1400,,,,,,,,,,,,,,,5.0,,,,59.0,Days,Dead,95.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Lysate
1401,,,,,,,,,,,,,,,5.0,,,,64.0,Days,Dead,157.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1402,,,,,,,,,,,,,,,3.0,,,,63.0,Days,Dead,72.0,,Colon cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1403,,,,,,,,,,,,,,,6.0,,,,38.0,Days,Live,397.0,,Melanoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1404,,,,,,,,,,,,,,,3.0,,,,31.0,Days,Dead,81.0,,Ovarian cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1405,,,,,,,,,,,,,,,4.0,,,,56.0,Days,Dead,117.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1406,,,,,,,,,,,,,,,4.0,,,,50.0,Days,Dead,74.0,,Cervical cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1407,,,,,,,,,,,,,,,6.0,,,,69.0,Days,Live,342.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1408,,,,,,,,,,,,,,,4.0,,,,62.0,Days,Dead,184.0,,Lung cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1409,,,,,,,,,,,,,,,4.0,,,,70.0,Days,Dead,116.0,,Colon cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1410,,,,,,,,,,,,,,,6.0,,,,51.0,Days,Dead,136.0,,Breast cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1411,,,,,,,,,,,,,,,3.0,,,,59.0,Days,Dead,149.0,,Prostate cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1412,,,,,,,,,,,,,,,4.0,,,,70.0,Days,Dead,123.0,,Stomach cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1413,,,,,,,,,,,,,,,6.0,,,,71.0,Days,Dead,171.0,,Colon cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1414,,,,,,,,,,,,,,,6.0,,,,66.0,Days,Dead,173.0,,Ovarian cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,RNA
1415,,,,,,,,,,,,,,,6.0,,,,55.0,Days,Dead,315.0,,Prostate cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1416,,,,,,,,,,,,,,,6.0,,,,57.0,Days,Dead,152.0,,Melanoma,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1417,,,,,,,,,,,,,,,6.0,,,,54.0,Days,Dead,198.0,,Ovarian cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1418,,,,,,,,,,,,,,,5.0,,,,51.0,Days,Dead,176.0,,Ovarian cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1419,,,,,,,,,,,,,,,6.0,,,,67.0,Days,Dead,356.0,,Prostate cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,RNA
1420,,,,,,,,,,,,,,,6.0,,,,62.0,Days,Dead,207.0,,Melanoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1421,,,,,,,,,,,,,,,6.0,,,,70.0,Days,Live,450.0,,Melanoma,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1422,,,,,,,,,,,,,,,6.0,,,,40.0,Days,Live,528.0,,Lung cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,RNA
1423,,,,,,,,,,,,,,,6.0,,,,42.0,Days,Live,454.0,,Ovarian cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1424,,,,,,,,,,,,,,,6.0,,,,73.0,Days,Live,458.0,,Prostate cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,RNA
1425,,,,,,,,,,,,,,,4.0,,,,36.0,Days,Dead,87.0,,Colon cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,RNA
1426,,,,,,,,,,,,,,,5.0,,,,60.0,Days,Live,498.0,,Ovarian cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,RNA
1427,,,,,,,,,,,,,,,6.0,,,,60.0,Days,Live,462.0,,Ovarian cancer,,,,,,,,,,,Partial Response,,,,,,Female,,,,,RNA
1428,,,,,,,,,,,,,,,6.0,,,,68.0,Days,Live,463.0,,Prostate cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,RNA
1429,,,,,,,,,,,,,,,5.0,,,,42.0,Days,Dead,246.0,,Cervical cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1430,,,,,,,,,,,,,,,6.0,,,,56.0,Days,Dead,193.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1431,,,,,,,,,,,,,,,6.0,,,,61.0,Days,Live,493.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1432,,,,,,,,,,,,,,,6.0,,,,33.0,Days,Live,485.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1433,,,,,,,,,,,,,,,6.0,,,,38.0,Days,Live,451.0,,Breast cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1434,,,,,,,,,,,,,,,6.0,,,,57.0,Days,Dead,417.0,,Lung cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,RNA
1435,,,,,,,,,,,,,,,6.0,,,,54.0,Days,Live,383.0,,Cervical cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,RNA
1436,,,,,,,,,,,,,,,2.0,,,,54.0,Days,Live,397.0,,Renal cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1437,,,,,,,,,,,,,,,3.0,,,,54.0,Days,Dead,439.0,,Colon cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,RNA
1438,,,,,,,,,,,,,,,5.0,,,,59.0,Days,Dead,95.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Lysate
1439,,,,,,,,,,,,,,,5.0,,,,64.0,Days,Dead,157.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1440,,,,,,,,,,,,,,,3.0,,,,63.0,Days,Dead,72.0,,Colon cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1441,,,,,,,,,,,,,,,6.0,,,,38.0,Days,Live,397.0,,Melanoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1442,,,,,,,,,,,,,,,3.0,,,,31.0,Days,Dead,81.0,,Ovarian cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1443,,,,,,,,,,,,,,,4.0,,,,56.0,Days,Dead,117.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1444,,,,,,,,,,,,,,,4.0,,,,50.0,Days,Dead,74.0,,Cervical cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1445,,,,,,,,,,,,,,,6.0,,,,69.0,Days,Live,342.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1446,,,,,,,,,,,,,,,4.0,,,,62.0,Days,Dead,184.0,,Lung cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1447,,,,,,,,,,,,,,,4.0,,,,70.0,Days,Dead,116.0,,Colon cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1448,,,,,,,,,,,,,,,6.0,,,,51.0,Days,Dead,136.0,,Breast cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,RNA
1449,,,,,,,,,,,,,,,3.0,,,,59.0,Days,Dead,149.0,,Prostate cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1450,,,,,,,,,,,,,,,4.0,,,,70.0,Days,Dead,123.0,,Stomach cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,RNA
1451,,,,,,,,,,,,,,,3.0,4500000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1452,,,,,,,,,,,,,,,,8900000.0,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1453,,,,,,,,,,,,,,,,9500000.0,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1454,,,,,,,,,,,,,,,,4700000.0,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1455,,,,,,,,,,,,,,,,10600000.0,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1456,,,,,,,,,,,,,,,,11.2,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1457,,,,,,,,,,,,,,,,6.5,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1458,,,,,,,,,,,,,,,,6.9,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1459,,,,,,,,,,,,,,,,9.4,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1460,,,,,,,,,,,,,,,,5.2,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1461,,,,,,,,,,,,,,,,10.7,,,,,,,,,,,,,,,,,,,,,,,,Significant,,,Immunotherapy,,,
1462,,,,,,,,,,,,,,,,8.9,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1463,,,,,,,,,,,,,,,,12.1,,,,,,,,,,,,,,,,,,,,,,,,Significant,,,Immunotherapy,,,
1464,,,,,,,,,,,,,,,,4.8,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1465,,,,,,,,,,,,,,,,4.8,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1466,,,,,,,,,,,,,,,,7.9,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1467,,,,,,,,,,,,,,,,12.5,,,,,,,,,,,,,,,,,,,,,,,,Significant,,,Immunotherapy,,,
1468,,,,,,,,,,,,,,,,5.1,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1469,,,,,,,,,,,,,,,,5.6,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1470,,,,,,,,,,,,,,,,4.3,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1471,,,,,,,,,,,,,,,,7.8,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1472,,,,,,,,,,,,,,,,6.5,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1473,,,,,,,,,,,,,,,,11.0,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1474,,,,,,,,,,,,,,,,9.8,,,,,,,,,,,,,,,,,,,,,,,,Significant,,,Immunotherapy,,,
1475,,,,,,,,,,,,,,,,10.2,,,,,,,,,,,,,,,,,,,,,,,,Significant,,,Immunotherapy,,,
1476,,,,,,,,,,,,,,,,7.0,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1477,,,,,,,,,,,,,,,,4.9,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1478,,,,,,,,,,,,,,,,4500000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1479,,,,,,,,,,,,,,,,8900000.0,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1480,,,,,,,,,,,,,,,,9500000.0,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1481,,,,,,,,,,,,,,,,4700000.0,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1482,,,,,,,,,,,,,,,,10600000.0,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1483,,,,,,,,,,,,,,,,11.2,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1484,,,,,,,,,,,,,,,,6.5,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1485,,,,,,,,,,,,,,,,6.9,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1486,,,,,,,,,,,,,,,,9.4,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1487,,,,,,,,,,,,,,,,5.2,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1488,,,,,,,,,,,,,,,,10.7,,,,,,,,,,,,,,,,,,,,,,,,Significant,,,Immunotherapy,,,
1489,,,,,,,,,,,,,,,,8.9,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1490,,,,,,,,,,,,,,,,12.1,,,,,,,,,,,,,,,,,,,,,,,,Significant,,,Immunotherapy,,,
1491,,,,,,,,,,,,,,,,4.8,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1492,,,,,,,,,,,,,,,,4.8,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1493,,,,,,,,,,,,,,,,7.9,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1494,,,,,,,,,,,,,,,,12.5,,,,,,,,,,,,,,,,,,,,,,,,Significant,,,Immunotherapy,,,
1495,,,,,,,,,,,,,,,,5.1,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1496,,,,,,,,,,,,,,,,5.6,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1497,,,,,,,,,,,,,,,,4.3,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1498,,,,,,,,,,,,,,,,7.8,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1499,,,,,,,,,,,,,,,,6.5,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1500,,,,,,,,,,,,,,,,11.0,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1501,,,,,,,,,,,,,,,,9.8,,,,,,,,,,,,,,,,,,,,,,,,Significant,,,Immunotherapy,,,
1502,,,,,,,,,,,,,,,,10.2,,,,,,,,,,,,,,,,,,,,,,,,Significant,,,Immunotherapy,,,
1503,,,,,,,,,,,,,,,,7.0,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1504,,,,,,,,,,,,,,,,4.9,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1505,,,,,,,,,,,,,,,4.0,4500000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,,Peptide
1506,,,,,,,,,,,,,,,,8900000.0,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1507,,,,,,,,,,,,,,,,9500000.0,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1508,,,,,,,,,,,,,,,,4700000.0,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1509,,,,,,,,,,,,,,,,10600000.0,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1510,,,,,,,,,,,,,,,,11.2,,,,,,,,,,,,,,,,,,,,,,,,None,,,Immunotherapy,,,
1511,,,,,,,,,,,,,,,1.0,,,,,Months,Live,20.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,None,Female,,,,,
1512,,,,,,,,,,,,,,,1.0,,,,,Months,Dead,20.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,Not significant,Male,,,,,
1513,,,,,,,,,,,,,,,1.0,,,,,Months,Dead,20.0,,,,,,,,,,,,Chemotherapy,Partial Response,,,,,Not significant,Male,,,,,
1514,,,,,,,,,,,,,,,2.0,,,,,Months,Dead,19.0,,,,,,,,,,,,,Stable Desease,,,,,Not significant,Male,,,,,
1515,,,,,,,,,,,,,,,6.0,,,,,Months,Dead,19.0,,,,,,,,,,,,,Partial Response,,,,,Not significant,Male,,,,,
1516,,,,,,,,,,Tumor antigen,No,,,20000000.0,4.0,,,,51.0,Months,Dead,18.0,,Renal cancer,Normal,1.0,1.0,,,,,TNF-α,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Subcutaneously,,
1517,,,,,,,,,,,,,,,1.0,,,,,Months,Dead,17.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
1518,,,,,,,,,,Tumor antigen,No,,,20000000.0,4.0,,,,51.0,Months,Dead,18.0,,Renal cancer,Normal,1.0,1.0,,,,,TNF-α,Monocytes,,Partial Response,,,,,Not significant,Male,,Immunotherapy,Subcutaneously,,
1519,,,,,,,,,,,,,,,2.0,,,,,Months,Dead,21.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
1520,,,,,,,,,,,,,,,3.0,,,,,Months,Dead,16.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
1521,,,,,,,,,,,,,,,1.0,,,,,Months,Dead,16.0,,,,,,,,,,,,,Partial Response,,,,,,Male,,,,,
1522,,,,,,,,,,,,,,,1.0,,,,,Months,Dead,15.0,,,,,,,,,,,,,Progressive Disease,,,,,None,Male,,,,,
1523,,,,,,,,,,,,,,,1.0,,,,,Months,Dead,10.0,,,,,,,,,,,,,Complete response,,,,,,Male,,,,,
1524,,,,,,,,,,,,,,,1.0,,,,,Months,Dead,10.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
1525,,,,,,,,,,,,,,,3.0,,,,,Months,Dead,9.0,,,,,,,,,,,,,Partial Response,,,,,,Male,,,,,
1526,,,,,,,,,,,,,,,3.0,,,,,Months,Dead,10.0,,,,,,,,,,,,,Complete response,,,,,,Male,,,,,
1527,,,,,,,,,,,,,,,1.0,,,,,Months,Dead,15.0,,,,,,,,,,,,,Complete response,,,,,,Male,,,,,
1528,,,,,,,,,,,,,,,1.0,,,,,Months,Dead,12.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
1529,,,,,,,,,,,,,,,1.0,,,,,Months,Dead,21.0,,,,,,,,,,,,,Partial Response,,,,,,Male,,,,,
1530,,,,,,,,,,,,,,,1.0,,,,,Months,Dead,15.0,,,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,
1531,,,,,,,,,,,,,,,2.0,,,,,Months,Dead,16.0,,,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,
1532,,,,,,,,,,,,,,,2.0,,,,,Months,Dead,20.0,,,,,,,,,,,,Immunotherapy,Complete response,,,,,,Male,,,,,
1533,,,,,,,,,,,,,,,3.0,,,,,Months,Dead,6.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
1534,,,,,,,,,,,,,,,1.0,,,,,Months,Dead,4.0,,,,,,,,,,,,,Death,,,,,,Female,,,,,
1535,,,,,,,,,,,,,,,3.0,,,,,Months,Dead,6.0,,,,,,,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1536,,,,,,,,,,,,,,,2.0,,,,,Months,Dead,11.0,,,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
1537,,,,,,,,,,,,,,,2.0,,,,,Months,Dead,5.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
1538,,,,,,,,,,,,,,,2.0,,,,,Months,Dead,5.0,,,,,,,,,,,,Immunotherapy,Stable Desease,,,,,,Male,,,,,
1539,,,,,,,,,,,,,,,,,,,66.0,,,,,,,,,,,,80.0,,,Surgery,,,,,,,Female,,,,,
1540,,,,,,,,,,,,,,,,,,,59.0,,,,,,,,,,,,80.0,,,Surgery,,,,,,,Female,,,,,
1541,Tumor antigen,No,,,Tumor antigen,Yes,1.0,44.0,,Tumor antigen,Yes,,,10000000.0,3.0,,,,66.0,Months,Live,6.0,,Glioblastoma,Normal,,,,100.0,60.0,70.0,TNF-α,Monocytes,Radiotherapy,,,,,,Not significant,Female,,,Intralymphatically,,Lysate
1542,,,,,,,,,,,,,,,,,,,66.0,,,,,,,,,,,,80.0,,,Surgery,,,,,,,Male,,,,,
1543,,,,,,,,,,,,,,,,,,,78.0,,,,,,,,,,,,70.0,,,Surgery,,,,,,,Male,,,,,
1544,,,,,,,,,,,,,,,,,,,54.0,,,,,,,,,,,,80.0,,,Surgery,,,,,,,Female,,,,,
1545,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,,,90.0,,,Surgery,,,,,,,Female,,,,,
1546,Tumor antigen,No,,,Tumor antigen,Yes,1.0,44.0,,Tumor antigen,Yes,,,10000000.0,3.0,,,,57.0,Months,Live,6.0,,Glioblastoma,Normal,,,,100.0,60.0,70.0,TNF-α,Monocytes,Radiotherapy,,,,,,Not significant,Male,,,Intralymphatically,,Lysate
1547,Tumor antigen,No,,,Tumor antigen,Yes,1.0,44.0,,Tumor antigen,Yes,,,10000000.0,3.0,,,,48.0,Months,Live,6.0,,Glioblastoma,Normal,,,,100.0,60.0,90.0,TNF-α,Monocytes,Chemotherapy,,,,,,Not significant,Male,,,Intralymphatically,,Lysate
1548,,,,,,,,,,,,,,,,,,,59.0,,,,,,,,,,,,90.0,,,Surgery,,,,,,,Male,,,,,
